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10.1
INTRODUCTION
This chapter will introduce you to key issues and resources in access to medicines and human rights. In 
addition, this chapter will help you understand why, more now than ever, access to medicines must be 
understood and approached as a human rights issue. 
Some of these issues are also addressed in Chapter 1 on Patient Care, Chapter 2 on HIV/AIDS, Chapter 3 
on Tuberculosis and Human Rights, and Chapter 5 on Palliative Care and Human Rights.
The chapter is organized into five sections that answer the following questions:
1. How is access to medicines a human rights issue?
2. What is a human rights-based approach to advocacy, litigation, and programming?
3. What are some examples of effective human rights-based work in the area of access to medicines?
4. Where can I find additional resources on human rights-based approach to access to medicines?
5. What are key terms related to a human rights-based approach to access to medicines?
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1. HOW IS ACCESS TO MEDICINES A HUMAN  
 RIGHTS ISSUE?
 
What is access to medicines?
In 2015, the international community adopted the Sustainable Development Goals (SDGs), a set of 17 goals 
to be achieved by 2030. Goal 3 — which committed to “ensure healthy lives and promote well-being for all 
at all ages” — proposed a range of targets from addressing non-communicable diseases to substance abuse 
to environmental health. Imbedded in the fulfilment of Goal 3 was the target to end the epidemics of AIDS, 
tuberculosis, malaria, and neglected tropical diseases, and to combat hepatitis, water-borne diseases, and 
other communicable diseases. Goal 3 also called for the achievement of universal health coverage, greater 
investment in research and development of medicines for communicable and noncommunicable diseases, 
and as this chapter of the Health and Human Rights Resource Guide will discuss, the provision of access to 
affordable essential medicines.
What are essential medicines? By definition, essential medicines are those medicines that “satisfy the priority 
healthcare needs of the population,” and according to the World Health Organization (WHO), are selected 
on the basis of their estimated current and future public health relevance, evidence of efficacy and safety, and 
comparative cost-effectiveness. Medicines that meet these principles are published in the WHO’s model list 
of essential medicines, an inventory updated every two years and tailored to national or regional health needs 
in a national essential medicines list (EML). Countries can use national lists as a tool to prioritize their most 
pressing public health needs by focusing on public sector procurement and treatment of a limited and high-
priority set of medicines. 
Advances in scientific and technological innovation over the past several decades have changed the current 
picture of the world’s access to medicines. Innovation has motivated the development of new vaccines, 
reduced the prevalence of infectious diseases (for instance, polio and human papillomavirus),1 and significantly 
decreased the global disease burden of HIV/AIDS. The invention of molecularly targeted therapies has even 
showed early promise for treating cancer, and the biomedical industry has made strides in strengthening 
the prevention, treatment, and control of transmissible and non-transmissible diseases. 2 Tuberculosis is 
illustrative of this progress: Between 1990 and 2013, the tuberculosis mortality rate fell by 45 percent, and the 
prevalence rate fell by 41 percent.3
Despite notable progress, approximately 2 billion people around the world still face tremendous obstacles in 
accessing the medicines they need.4 Moreover, the current research and development (R&D) model, which is 
largely market driven, is ill-equipped to address these gaps. It also should be noted that now more than ever, 
the high pricing of essential medicines is increasingly understood as a global problem affecting all countries, 
not just developing ones. While in the late nineties, the HIV/AIDS epidemic was the hallmark example of 
access problems, this picture has changed (prices of ARVs have come down to close to marginal cost of 
production in most countries, and at the end of 2014, 13.6 million people were able to access antiretroviral 
1.     High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: Promoting 
Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 3.
2  Ibid., 3.
3  United Nations (UN), “Goal 3: Ensure healthy lives and promote well-being for all at all ages,” SDGs fact sheet, http://www.un.org/
sustainabledevelopment/health/.
4  Access to Medicine Foundation, “The 2016 Access to Medicine Index: Methodology 2015,” 2016, http://apps.who.int/medicinedocs/documents/
s22176en/s22176en.pdf [accessed April 27, 2017].
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therapy 5,6), and the prevailing R&D model has us ill-prepared to respond to emerging infectious diseases 
such as Zika and Ebola; to neglected tropical diseases (NTDs) that predominantly affect populations with 
little purchasing power;7 and to neglected populations, such as people living with rare diseases and children. 
The human rights-based approach put forth by this chapter will provide recommendations to resolve this 
incoherence between innovation and access by realigning global public health priorities and global health 
technology innovation.
This chapter intends to develop the current understanding of a human rights-based approach to access to 
medicines: it outlines the challenges that many populations face in accessing medicines (Section 1, part 
I), explains what understanding access to medicines through a human-rights based lens means (part II), 
summarizes human rights elements necessary for the realization of access to medicines (part III), and 
examines the tension between intellectual property (IP) rights and international human rights commitments 
(part IV). Part V focuses on key populations that encounter specific challenges within the broad landscape 
of enabling access to medicines, and Part VI recommends rights-based interventions and practices. After 
a tabular overview of the most relevant international and regional human rights standards related to the 
topic (Section 2), Section 3 discusses relevant human rights-based approaches to advocacy, litigation, and 
programming. Section 4 highlights specific country examples that have been successful in advancing the right 
to health and access to medicines for all, and the final section offers a glossary for further reading.
What are the issues and how are they human rights issues?
 I. An overview of the international human rights framework 
Access to essential medicines, nested in the right to the highest attainable standard of health, is well 
founded in international law. The 1946 Constitution of the World Health Organization and the 1948 Universal 
Declaration of Human Rights (UDHR) both expressly recognize the right to health. The 1966 International 
Covenant on Economic, Social, and Cultural Rights (ICESCR), which has 164 states parties, elaborates that 
the right to health includes “access to health facilities, goods, and services.” In General Comment 14 (2000) 
on the right to health, the Committee on Economic, Social and Cultural Rights (CESCR) interprets the 
normative content of article 12 of the ICESCR.8 Although the ICESCR only requires the progressive realization 
of the right to health in the context of limited resources, there is a core set of minimum obligations which 
are not subject to progressive realization, including access to essential medicines.9 The WHO, numerous 
national court cases and resolutions of the Human Rights Council, and the Doha Declaration on TRIPS and 
Public Health reaffirm access to essential medicines as a human right that must be available “for all.”  
While states hold the core responsibility for essential medicines provision, these responsibilities are shared 
with other non-state actors. For example, pharmaceutical companies have human rights responsibilities 
described by the former UN Special Rapporteur on the Right to Health, including the duty to take all 
5  United Nations (UN), “Goal 3: Ensure healthy lives and promote well-being for all at all ages,” SDGs fact sheet, http://www.un.org/
sustainabledevelopment/health/.
6  While access to treatment for HIV/AIDS is still a challenge for many, “new HIV infections in 2013 were estimated at 2.1 million, which was 38 per cent 
lower than in 2001.” United Nations (UN), “Goal 3: Ensure healthy lives and promote well-being for all at all ages,” SDGs fact sheet, http://www.un.org/
sustainabledevelopment/health/.
7  In 2014 alone NTDs affected an estimated 1.7 billion people. However, insufficient R&D is invested in treating and preventing NTDs, “further amplified 
by the fact that many [of these diseases] require chronic and costly care.” WHO, World Health Statistics 2016: Monitoring Health for the Sustainable 
Development Goals (Geneva: WHO, 2016) in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-
Level Panel on Access to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 13.
8  UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14, U.N. Doc. E/C.12/2000/4 (August 11, 2000).
9  Ibid, paragraph 43(d).
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reasonable measures to make new medicines “as available as possible” for those in need.10 Additionally, 
the UN Guiding Principles on Business and Human Rights, which were unanimously endorsed by the UN 
Human Rights Council in 2011, obliges the private sector to take responsibility for violations of human rights 
related to access to medicines.11 The international community also has human rights obligations to assist 
governments lacking resources to achieve their minimum core duties through international cooperation and 
assistance.12 In the face of disaster, the international community bears the duty to contribute to relief and 
humanitarian assistance by providing medical supplies as a matter of priority.13
II. What does a human rights-based approach (HRBA) contribute to access to medicines?
What does a human rights-based approach (HRBA) contribute to access to medicines? A HRBA identifies 
all human beings as having indivisible, interrelated rights, and in this case, to health and to access essential 
medicines. In addition to duties and entitlements, and as articulated by the WHO14 and CESCR,15 a HRBA 
applies the principles of non-discrimination and equality; participation and inclusion; accountability; and the 
rule of law to universal access policies.16  These principles are conceived to inform all stages of programming 
and advocacy work, including monitoring and evaluation. A HRBA to access to medicines draws special 
attention to marginalized, disadvantaged, and excluded populations and endows all populations with the 
ability to achieve outcomes through an inclusive, transparent, and responsive process.17,18 
A human rights-based approach can also be applied to improve access to medicines at the policy level. The 
right to health offers a framework from which national health policies and laws can be shaped for universal 
and equitable access. The result can manifest as positive health outcomes and the individual realization 
of health rights and access to medicines. For instance, domestic constitutions that recognize access to 
medicines as part of the right to health can support individual claims for essential medicines in national 
courts.19 A good example of this is documented in the final section of this chapter, where the right to health 
ratified by the Kenyan Constitution played a role in supporting litigation that ultimately advanced access to 
ARVs for people living with and affected by HIV and AIDS.
For individuals and communities living in relative poverty, recasting their lack of access to health care and 
essential medicines not as a failure of government policy, but as a denial of their rights, is tremendously 
empowering. When the needs essential to a life lived in dignity are elevated to the rank of legal 
entitlements, they have the power to change political discourse and the horizon of social expectations.20 
10   UN General Assembly, The Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health: Report of the Special 
Rapporteur, Paul Hunt, U.N. General Assembly, 63rd Session, Agenda Item 67(b), U.N. Doc, A/63/263 (August 11, 2008).
11  John Ruggie, Report of the Special Representative of the Secretary-General on the Issue of Human Rights and Transnational Corporations and Other 
Business Enterprises: ‘Protect, Respect and Remedy: A Framework for Business and Human Rights’, A/HRC/8/5 (April 7, 2008). 
12 Article 2(1) of the ICESCR calls upon all states, individually “and through international assistance and cooperation,” to guarantee the progressive 
realization of human rights.
13 UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14, para. 40.
14 Xavier Seuba states that “WHO mentions the recognition of access to essential medicines as a human right at the state level among the priorities in 
the framework of implementation of pharmaceutical policies in the period 2004-2007, and WHO’s joint effort with the United Nations Committee on 
Economic, Social, and Cultural Rights has resulted in the inclusion of access to essential medicines in the core content of the right to health. See Xavier 
Seuba, “Round Table: A Human Rights Approach to the WHO Model List of Essential Medicines,” Bulletin of the World Health Organization 84 (2006), 
http://apps.who.int/medicinedocs/documents/s21845en/s21845en.pdf, 405-411.
15 See UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14, U.N. Doc. E/C.12/2000/4 (August 11, 2000).
16 For a brief explanation of these principles, see UN Development Group (UNDG), The Human Rights Based Approach to Development Cooperation Towards 
a Common Understanding Among UN Agencies (May 2003),  http://hrbaportal.org/the-human-rights-based-approach-to-development-cooperation-
towards-a-common-understanding-among-un-agencies. 
17 UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14, U.N. Doc. E/C.12/2000/4 (August 11, 2000).
18 OHCHR/WHO, The Right to Health, Factsheet No. 31, 2008.
19    Hans V. Hogerzeil, Melanie Samson, Jaume Vidal Casanovas, et al., “Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health     
Enforceable through the Courts?” Lancet 368 (July 2006), pp. 305-11, http://cdrwww.who.int/medicines/news/Lancet_EssMedHumanRight.pdf.
20 I. Khan and D. Petrasek, “Beyond the Courts – Protecting Economic and Social Rights,” OpenDemocracy, 2014, https://www.opendemocracy.net
        openglobalrights/irene-khan-david-petrasek/beyond-courts-%E2%80%93-protecting-economic-and-social-rights [accessed April 27, 2017].
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Reframing health as a human right is not simply to appear in court; it is to expand the bounds of what 
is possible, to mobilize neglected communities, to raise public awareness and trigger activism and 
education. 
Importantly, application of the human rights framework also provides a clear delineation of the spheres 
of responsibility of different stakeholders, as circumscribed by human rights treaties, guiding principles, 
and general comments. States are obliged under international human rights law to respect, protect, and 
fulfill the right to health, which includes an obligation to adopt legislative, administrative, and budgetary 
measures to facilitate access to medicines that are affordable, accessible, culturally acceptable, and of good 
quality.21 This obligation for a state to “use all available resources at its disposal”22 to satisfy its obligations 
with respect to health will often require a state to make full use of the public health flexibilities available 
under international law.23 
Meanwhile, pharmaceutical companies bear a responsibility to respect human rights vis-à-vis the Ruggie 
trinity of protect, respect, and remedy.24 Within this framework, corporations have a duty to (a) avoid causing 
or contributing to adverse human rights impacts through their own activities, and address such impacts 
when they occur; and (b) prevent or mitigate adverse human rights impacts that are directly linked to their 
operations, products, or services by their business relationships, even if they have not contributed to those 
impacts.25 Essentially, pharmaceutical firms bear a responsibility to act with due diligence to avoid infringing 
on the right to health. These responsibilities come into stark relief when pharmaceutical firms prioritize the 
enforcement of their intellectual property rights at the expense of their right-to-health obligations. 
III. Human rights elements for access to medicines
According to General Comment 14, realizing the right to access medicines is contingent upon the realization 
of four interrelated elements. Medicines must be (1) available, (2) accessible (with accessibility implying 
affordability, physical accessibility, and accessibility of information), (3) acceptable, and (4) of good quality.26
In complement to the “AAAQ” framework described above, WHO has outlined the following four key building 
blocks as essential toward ensuring access to medicines in national health systems:
“1. Rational selection and use of essential medicines, based on national lists of essential medicines 
and treatment guidelines;
2. Affordable prices for governments, health care providers and individuals;
21  ICESCR Committee General Comment No. 14.
22 See CESCR General Comment No. 14: “If resource constraints render it impossible for a State to comply fully with its Covenant obligations, it has the  
        burden of justifying that every effort has nevertheless been made to use all available resources at its disposal  in order to satisfy … the obligations
        outlined above.”
23 See the public health flexibilities available under TRIPS, for example, compulsory licensing, parallel importation, and discretion in defining domestic  
standards of patentability.
24 States have a duty to protect human rights, corporations have a duty to respect human rights, and states must ensure that there is access to effective  
remedy when abuses occur within their territory and/or jurisdiction.
25 John Ruggie, Report of the Special Representative of the Secretary-General on the Issue of Human Rights and Transnational Corporations and Other 
Business Enterprises: ‘Protect, Respect and Remedy: A Framework for Business and Human Rights’, A/HRC/8/5 (April 7, 2008). For additional normative 
statements on the human rights responsibilities of corporations, see: the UN Sub-Commission on the Promotion and Protection of Human Rights; the 
UN Global Compact, and the Organization for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises.      
26   UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14, U.N. Doc. E/C.12/2000/4 (August 11, 2000).
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3. Fair and sustainable financing of essential medicines as part of the national health care system 
through adequate funding levels and equitable prepayments systems, to ensure that the poor are 
not disproportionately affected by medicine prices; and
4. Reliable health and supply systems to ensure sufficient and a locally appropriate combination of 
public and private service providers.”27
Article 2 (1) of the ICESCR also calls for the “progressive realization” of economic and social rights. In other 
words, the ICESCR recognizes that some states are burdened by resource constraints, and therefore, allows 
obligations to be realized over time. Therefore, in theory, a lack of resources can justify non-compliance. 
However, as it was just mentioned and as the Limburg Principles on the Implementation of the International 
Covenant on Economic, Social and Cultural Rights have elaborated, the progressive realization of rights 
also suggests that states, regardless of their level of economic development, are obligated to take measures 
immediately and “move as expeditiously as possible” towards the realization of those rights.28 Within the 
context of medicines, states must create and implement a reasonable action program to continuously improve 
access to essential medicines. State responsibility to provide essential medicines should be recognized in 
domestic law and given priority for public financing through sufficient budget allocation. Laws and policies 
within the health system (i.e. for universal health coverage or medicines pricing) and the broader legal 
order (i.e. for trade or intellectual property protection) should be aligned with achieving universal access 
to essential medicines. For instance, governments should make full use of the trade options under TRIPS 
flexibilities to safeguard access to essential medicines. (For an introduction on the TRIP Agreement and 
TRIPS flexibilities, see page 1-13.)
Regional instruments and documents agreed upon by the health community also clearly recognize the right 
to health. The African Charter on Human and Peoples’ Rights (art. 16), the European Social Charter (art. 11), 
the Protocol of San Salvador (art. 10),29 the WHO Constitution,30 the Ottawa Charter for Health Promotion,31 
and the Bangkok Charter for Health Promotion in a Globalized World32 all consider health a fundamental 
human right.33 These agreements can support access to medicines claims in domestic courts. In addition, 
the 1978 Declaration of Alma-Ata establishes a clear and important link between the provision of primary 
health care and the provision of essential drugs.34 
International law gives clear guidance to states, and their implementation should be monitored in practice. 
Although more than 30 countries have not ratified the ICESCR, most states are party to at least one human 
rights instrument that recognizes the right to health. 
27 WHO, “Equitable Access to Essential Medicines: A Framework for Collective Action” in WHO Policy Perspectives on Medicines Bulletin (2004), 
http://apps.who.int/medicinedocs/pdf/s4962e/s4962e.pdf, 2.
28 See the Limburg Principles, https://www.escr-net.org/docs/i/425445. 
29 See Additional Protocol to the American Convention on Human Rights in the Area of Economic, Social And Cultural Rights, “Protocol of 
San Salvador,” http://www.oas.org/juridico/english/treaties/a-52.html. 
30 WHO, Constitution of the World Health Organization, http://www.who.int/gb/bd/PDF/bd46/ebd46_p2.pdf. 
31 WHO, Declaration of Alma-Ata, International Conference on primary health care, Alma-Ata, USSR, September 6–12, 1978, http://www.
searo.who.int/LinkFiles/Health_Systems_declaration_ almaata.pdf.  
32 WHO, The Bangkok Charter for Health Promotion in a Globalized World, 2005, http://www.who.int/healthpromotion/conferences/ 6gchp/
hpr_050829_%20BCHP.pdf. 
33   Gunilla Backman, Paul Hunt, Rajat Khosla, et al., “Health Systems and the Right to Health: An Assessment of
 194 Countries,” Lancet 372 (2008), 2047–85, http://www.who.int/medicines/areas/human_rights/Health_System_HR_194_countries.pdf. 
34   WHO, Declaration of Alma-Ata, International Conference on Primary Health Care, Alma-Ata, USSR, September 6-12, 1978, http://www.
searo.who.int/LinkFiles/Health_Systems_declaration_almaata.pdf [accessed Sept 21, 2008]. 
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In terms of recognition in domestic law, 105 national constitutions include a degree of protection of the right 
to public health or medical care, while only 13 constitutions include the access to medicines as part of the 
right to health.35,36 
IV. Intellectual property protection and trade
In addition to governments, non-state actors, such as pharmaceutical companies, have human rights 
responsibilities with respect to health. As explained by the UN Special Rapporteur on the right to health, 
Paul Hunt, pharmaceutical companies have the duty to take all reasonable steps to make a medicine “as 
accessible as possible” after it has been marketed, including to those who cannot afford (high) prices. 
These steps should be taken within a “viable business model.” 37 Paul Hunt contends that a company may 
be in breach of its responsibilities under the right to health “if a patent is worked without these steps being 
taken.”38
Even so, expanding economic globalization has tended to position the protection and enforcement of 
intellectual property (IP) rights at odds with international human rights law, and incoherencies have arisen 
between “patents” and “patients.” In 2015, the United Nations Secretary-General Ban Ki-moon recognized 
this tension when he established the UN High-Level Panel on Access to Medicines with a mandate to 
address the misalignment between the rights of inventors, international human rights law, trade rules, and 
public health. The culminating report posited that market-based models, which incentivize innovation, 
often lead to “insufficient investment… in R&D for diseases that predominantly affect the poor” and “prices 
charged by some right holders place severe burdens on health systems and individual patients, in wealthy 
and resource-constrained countries alike.”39 Among several recommendations, the report encouraged 
countries to reinforce the use of compulsory licenses through national laws, treat TRIPS flexibilities as a 
fundamental part of the TRIPS Agreement (not as an exception), and engage transparently in priority setting 
and coordination to prevent and stymie infectious diseases. It also encouraged the use of delinkage, a 
concept that refers to “delinking” the costs of R&D from the end prices of health technologies. 
Patents
Pharmaceutical companies apply for patents for new, useful, and non-obvious inventions.40 The public 
disclosure of an invention is rewarded with a twenty-year monopoly on its production, sale, and distribution. 
While pharmaceutical companies, and even governments, often claim that patents encourage innovation 
and provide crucial recuperation for research and development costs, the lack of transparency of R&D 
expenditure by the industry makes it almost impossible to determine the true costs of medicines.41  
35   Jody Heymann, Adèle Cassola, Amy Raub, et al., “Constitutional Rights to Health, Public Health and Medical Care: The Status of Health 
Protections in 191 Countries,” Global Public Health 8/6 (2013), pp. 639-653, http://www.tandfonline.com/doi/abs/10.1080/17441692.2013.81
0765.
36 S. Katrina Perehudoff, Brigit Toebes, and Hans Hogerzeil, “Essential Medicines in National Constitutions: Progress Since 2008,” Health and 
Human Rights 18/1 (June 2016), pp. 141–156, https://www.hhrjournal.org/2016/05/essential-medicines-in-national-constitutions-progress-
since-2008/. 
37 Paul Hunt and Rajat Khosla, “Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former 
United Nations Special Rapporteur (2002-2008),” PLoS Medicine 7/9 (2010), http://journals.plos.org/plosmedicine/article?id=10.1371/journal.
pmed.1000330. 
38 Ibid. 
39 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 16.
40.  See TRIPS Article 27: “[P]atents shall be available for any inventions, whether products or processes, in all fields of technology, provided that
       they are new, involve an inventive step and are capable of industrial application.”
41   Ellen ’t Hoen, Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The Netherlands: Health Action 
International, 2016), pg. 90.
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Moreover, data has shown that the patent system tends to disproportionately benefit the holders of patent 
rights in developed countries at the cost of patients who consume technologies and goods in developing 
countries.42,43
A patent confers so-called “negative rights” that allow the patent holder to exclude others from using his/
her invention. Granted by the state, patents allow companies to control the production, distribution, use by 
others, and importation, and therefore, the price, of the product in question. Monopoly market power often 
leads to excessive prices and restricted access to affordable treatments for populations in developing and 
developed countries.44,45 Increasingly, new essential medicines are priced out-of-reach of patients in high-
income countries as well.46 
The purpose of the patent system is to incentivize innovation by giving the patentee exclusive monopoly 
rights over the use of the patented technology for a limited period of time, in return for disclosing valuable 
knowledge to society. The social gains derived from this system of protection must always be weighed 
against the inefficiencies resulting from monopoly market power and its vulnerability to abuse. Striking 
the optimal balance between innovation and access is extremely complex and inevitably influenced by the 
socioeconomic development agenda of the particular territory in which patent rights are enjoyed.
The patent regime’s vulnerability to abuse, particularly with respect to medicines treating for serious 
conditions — like hepatitis C or cancer — can be a matter of life or death.47 As a UN expert consultant on 
access to medicines has written,
“While intellectual property rights have the important function of providing 
incentives for innovation, they can, in some cases, obstruct access by pushing up 
the price of medicines. The right to health requires a company that holds a patent on 
a lifesaving medicine to make use of all the arrangements at its disposal to render 
the medicine accessible to all.”48 
The use of patent monopolies to limit generic competition compromises the “accessibility” (through 
affordability) of medicines, an issue that has been hotly debated in many countries. For example, in South 
Africa, the use of patents to block access to low-cost generic medicines have historically been responsible 
for high-priced essential medicines for HIV/AIDS and cancer, denying access to life-saving treatment for 
many. Similar strategies to challenge patent rights have been initiated in other developing countries. For 
example, in India, a patent application for Lopinavir/ritonavir (a treatment for HIV) manufactured by Abbott 
Laboratories (now AbbVie), was refused after I-MAK, a U.S.-based not-for-profit, filed a pre-grant opposition 
42   Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and Development Policy: Report of the CIPR (London: UK
      Commission on Intellectual Property Rights, 2002), 21, quoted in Jennifer Sellin, Access to Medicines: The Interface Between Patents and Human 
Rights: Does One Size Fit All?, 81.
43 See also UN Sub-Commission on Human Rights, Resolution 2000/7, Intellectual Property Rights and Human Rights, U.N. Doc. A
      CN.4/L.682.
44 Global Commission on HIV and the Law, Risks, Rights and Health (New York: UNDP, July 2012), http://www.hivlawcommission.org
       resources/report/FinalReport-Risks,Rights&Health-EN.pdf. 
45 Médecins Sans Frontières (MSF), “The Impact of Patents on Access to Medicines,” MSF website, http://www.msfaccess.org/content/impact-
patents-access-medicines.
46   The European Consumer Organisation, Position on Access to Medicines (Brussels: BEUC, 2015), http://www.beuc.eu/publications
      beuc-x-2015-104_access_to_medicines.pdf. 
47 Ibid. 
48 UN General Assembly, Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of 
Physical and Mental Health - Expert Consultation on Access to Medicines as a Fundamental Component of the Right to Health, UN Doc. A/
HRC 17/43 (March 16, 2011).
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to it. I-MAK claimed that Abbott’s drug fell under Article 3(d) of the Indian patent law, which states “the 
mere discovery of a new form of a known substance which does not result in the enhancement of the known 
efficacy of that substance or the mere discovery of any new property or new use for a known substance or 
of the mere use of a known process, machine or apparatus unless such known process results in a new 
product or employs at least one new reactant.” I-MAK concluded that had Abbott secured a patent over a 
“new” formulation of Lopinavir/ritonavir, treatment for HIV/AIDS would have become out of reach for many. 
I-MAK’s litigation and advocacy work is highlighted in the best practices section (Section IV) of this chapter.
It is important to reverse the commonly held assumption that patent monopolies are the only means of 
recuperating the costs of, and therefore incentivizing, research and development for much-needed health 
technologies. While R&D is in fact needed to develop new drugs, a significant portion of this pivotal research 
is conducted with public financing. For example, advocates have pointed out that many antiretrovirals (anti-
HIV drugs) were developed in public-funded laboratories.49 Sofosbuvir, the high cost and highly effective 
drug for Hepatitis C, was also developed with public funding. Moreover, robust reports and analyses have 
also debunked the notion that patents are needed to recoup R&D costs.50 A report by the Commission on 
Intellectual Property Rights, Innovation and Public Health finds, “…[W]here the market has very limited 
purchasing power, as is the case for diseases affecting millions of poor people in developing countries, 
patents are not a relevant factor or effective in stimulating R&D and bringing new products to market.”51 
The introduction of the 1980 Bayh-Dole Act in the United States catalyzed significant research by allowing 
universities and public research institutions to patent the products of federally-funded research. However, 
limiting access to such discoveries through patent monopolies forces taxpayers to pay twice for the benefits 
of publicly-funded research.52 The provision of public funding for research and development should instead 
be conditioned on strong, enforceable policies with respect to data sharing, open access publishing, non-
exclusive licensing, participation in public sector patent pools, and affordability for low-income populations.53 
Unfortunately, R&D shortfalls are most pronounced in developing countries where high-priority diseases 
are concentrated. Since pharmaceutical companies use patents to prevent competition, they are able to 
retain monopoly pricing on their drugs, making purchasing them nearly impossible for patients who—many 
lacking health insurance—must pay out of pocket for these life-saving medicines.54
The TRIPS Agreement 
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into force in January 
1995 in response to the growing need for multilateral cooperation on the regulation of intellectual property 
(IP). Developed by the World Trade Organization (WTO), the TRIPS Agreement globalized intellectual prop-
erty requirements for the first time and marked a change in the way countries around the world interacted 
with the patent system. Prior to the establishment of TRIPS, intellectual property was regulated from country 
to country. 
49 Paul Farmer, Pathologies of Power: Health, Human Rights, and the New War on the Poor (Berkeley and Los Angeles: University of California 
       Press, 2013), 317.
50 The Commission on Intellectual Property Rights, Innovation and Public Health, Public Health, Innovation and Intellectual Property Rights 
       (Geneva: WHO, 2006), http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf?ua=1, 22.
51  Ibid.
52  High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
       Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 8. 
53  Ibid. 
54  Lisa Forman, “A Transformative Power? The Role of the Human Right to Medicines in Accessing AIDS Medicines – International Human  
       Rights Law, TRIPS, and the South African Experience” (SJD dissertation, University of Toronto, 2007).
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Governments were able to tailor laws, policies, and practices to meet national priorities, and in some cases, 
excluded pharmaceuticals from patent protection altogether in order to safeguard the public’s health. De-
scribing an age before the TRIPS Agreement, Ellen ‘T Hoen wrote, “The patenting of essential goods such 
as medicines and foods was long considered an act against the public interest.”55 
New provisions embedded within TRIPS required WTO members to provide patents for all new, non-
obvious, and useful inventions for at least 20 years (excluding the least developed countries and a few non-
WTO Members, such as Somalia).56 
Because patentability criteria are established by states and not by the WTO, states have significant discretion 
to define the parameters of patentability in a manner reflective of their domestic public health needs. For 
example, a developing country may decide to apply rigorous patentability criteria to ensure that generic 
firms are not unreasonably excluded from the market by incumbents who seek follow-on patents for new 
uses of known substances.57 Striking the optimal balance between innovation and access will inevitably 
require a consideration of both public health needs and the domestic socio-economic landscape. Overly 
stringent patentability criteria also has the potential to discourage investment by foreign firms who fear 
that their intellectual property may not be adequately protected, thereby potentially jeopardizing economic 
development plans. 
The DOHA Declaration
In November 2001 in Doha, Qatar, negotiations took place at the fourth WTO ministerial conference to 
address the TRIPS Agreement and the misalignment between profit-driven innovation models and public 
health. The result was the adoption of the Doha Declaration, a separate declaration on TRIPS and public 
health designed to respond to concerns about the implications of the TRIPS Agreement for access to 
medicines. 
The declaration clarified that the TRIPS Agreement “does not and should not prevent member governments 
from acting to protect public health.” It also emphasized governments’ right to use TRIPS “flexibilities,” 
which are safeguards imbedded within the TRIPS Agreement that enable countries to adopt provisions to 
ameliorate the impact of patents on their population’s public health. Acknowledging “the seriousness of the 
concerns expressed by the least-developed countries (LDCs),” the declaration allowed these countries not 
to grant or enforce pharmaceutical product patents until at least 2016.58 Paragraph 4 powerfully states, “[W]-
hile reiterating our commitment to the TRIPS Agreement, we affirm that the Agreement can and should be 
interpreted and implemented in a manner supportive of WTO Members’ right to protect public health and, 
in particular, to promote access to medicines for all.”59
To ensure strong IPR protection does not impede access to essential medicines, the declaration clarifies 
the scope of certain safeguards for all WTO members, which are embodied within the TRIPS Agreement. 
For instance, the declaration clarified that countries can determine the grounds upon which they issue 
55 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), 22.
56 World Trade Organization, “Intellectual Property: Protection and Enforcement” in Understanding the WTO: The Agreements, WTO fact sheet,
      https://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm. 
57 “Some governments, such as Brazil, Thailand or India, have done precisely that.” Médecins Sans Frontières (MSF), “TRIPS, TRIPS Plus and 
Doha,” July 2011, http://www.msfaccess.org/content/trips-trips-plus-and-doha. 
58 United States Trade Representative (USTR), The Doha Declaration On The Trips Agreement And Public Health, undated, https://ustr.gov/archive/
assets/Trade_Sectors/Intellectual_Property/Public_Health/asset_upload_file511_4113.pdf. 
59 Ibid. 
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compulsory licences for the generic manufacture of patented drugs.60 The Doha Declaration also recognized 
the rights of governments to choose their own regime for parallel importation. Parallel imports are authentic 
products sold under intellectual property protection (copyright, patent, or trademark) in one country and 
shipped to another country without the manufacturer’s permission.61 In the pharmaceutical context, parallel 
imports are genuine goods produced under patent, placed into circulation in one geographic market, and 
then imported into a second geographical market without the patentee’s authorization.62 The legality of 
parallel imports depends on the choice of territorial exhaustion of the patent holder’s rights: national 
exhaustion means that rights are exhausted upon first sale within a nation but patent owners may prohibit 
parallel imports from abroad; regional exhaustion permits parallel imports among member countries (for 
example, within the European Union) but not from outside the region; and international exhaustion permits 
parallel imports from anywhere in the world as the patent holder’s rights are considered to be exhausted 
upon first sale in any country.63 Typically, parallel importation is utilized to obtain drugs at their lowest price 
by exploiting price differences between markets. The Doha Declaration affirmed that countries are free to 
establish their own regime for parallel importation without challenge.64 
Finally, the Doha Declaration waived the obligation of least developed country members (LDCs) to provide 
patent protection for pharmaceutical inventions until January 1, 2016, a deadline which has now been 
extended to January 1, 2033.65 LDCs are also not required to provide patent protection to any invention at all 
until July 1, 2021, or until such a date on which they cease to be a least developed country member, whichever 
date is earlier.66
The Doha Declaration clarified that priorities under international trade law and international human rights 
law should be conversant with one another.67 However, the promise of the Doha Declaration, which sought 
to protect the public’s health, has recently come under threat as states engaged in trade negotiations are 
pressured by governments and pharmaceutical companies alike to adopt even stricter conditions in their 
patent laws. These conditions are known as “TRIPS-plus” provisions because they require stricter protection 
of intellectual property than is required by the TRIPS Agreement. (Stricter conditions put binding obligations 
on countries to implement certain IP provisions beyond what is required by TRIPS.) Included among these 
strategies are preventing generic producers from using clinical data from the patented medicine to enter 
the market (data exclusivity),68 and so-called patent “evergreening,” the practice of applying for multiple, 
successive patents on minor or insignificant variants or indications of already-patented compounds to extend 
the period of market exclusivity. While individual countries are free to implement strict patentability criteria 
that would prevent or limit evergreening, TRIPS-plus provisions, such as the obligation to grant patents for 
second medical use, would further facilitate the patenting of non-genuine innovations, or “evergreening.” 
60  World Trade Organization (WTO), Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2 (November 20, 2001), 
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm. 
61  C. Li and K. Maskus, “The Impact of Parallel Imports on Investments in Cost-Reducing Research and Development,” Journal of International 
Economics 68 (2006), 443-455.
62 K. Maskus, Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries, Final Report to World Intellectual 
      Property Organization (2001), http://www.wipo.int/export/sites/www/about ip/en/studies/pdf/ssa_maskus_pi.pdf [accessed January 24, 
      2017].
63 C. Li and K. Maskus, “The Impact of Parallel Imports on Investments in Cost-Reducing Research and Development,” Journal of International \
      Economics 68 (2006), 443-455.
64 World Trade Organization (WTO), Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2 (November 20, 2001),    
para 5(d). 
65 WTO, Extension of the Transition Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members for Certain 
      Obligations With Respect to Pharmaceutical Products, Decision of the Council for TRIPS of 6 November 2015 (2015), Doc No. IP/C/73. 
66 Ibid. 
67 Marceau, “WTO Dispute Settlement and Human Rights,” 755, in Jennifer Sellin, Access to Medicines. 
68 Joo-Young Lee, A Human Rights Framework for Intellectual Property, Innovation and Access to Medicines (Farnham, England: Ashgate Publishing 
      Limited, 2015).
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Both processes extend companies’ monopolies, often prolonging high prices on medicines. An example 
of an attempt to “evergreen,” employed by Abbott Laboratories, is highlighted in Section 4 of this chapter. 
I-MAK filed a pre-grant opposition in response, as a result of which the patent was not granted. The UN 
Secretary-General’s High Level Panel on Access to Medicines explicitly recommended that WTO members 
make full use of the policy space available in TRIPS Article 27 by adopting and applying rigorous definitions 
of invention and patentability to curtail evergreening and ensure that patents are awarded only for genuine 
innovations.69
Although the Doha Declaration encouraged greater use of the public health flexibilities available under 
TRIPS, some countries have been unable or unwilling to make greater use of them. To address this failing, 
several public interest organizations — CEHURD in Uganda is one example — have intervened. In a policy 
brief, CEHURD encouraged the Ugandan government to maximize public health benefits from the new IPR 
protection regime by “making the most” of all flexibilities within TRIPS and adopting only the minimum 
levels of IPR protection that the agreement requires. A case study outlining this work is highlighted at the 
end of this chapter (Section 4). Additionally, international and multilateral institutions, including the United 
Nations Development Programme (UNDP), WHO, UNITAID, and the Global Fund, have strongly supported 
and encouraged the use of TRIPS flexibilities. For instance, in 2016, UNITAID adopted a resolution on 
the use of the intellectual property flexibilities enshrined in the global trading system allowing developing 
countries to facilitate access to affordable medicines.70 
In addition, free trade agreements (FTAs) and investment treaties between states seek to build even 
stricter IP regimes that exceed the minimum provisions in the TRIPS Agreement through the inclusion of 
TRIPS-plus provisions.71 The United States, a principal exporter of intellectual property, has negotiated FTA 
agreements with Thailand, South Korea, Singapore and many other governments to increase the longevity 
of protection on patented drugs.72 TRIPS-plus provisions threaten to overshadow the utilization of public 
health safeguards to protect public health by, inter alia, requiring patents for new uses of known substances, 
prohibiting pre-grant opposition, imposing data exclusivity periods, extending patent terms beyond twenty 
years for regulatory or marketing delays, and imposing restrictions on compulsory licensing and parallel 
imports.73,74 The 2009 Report of the Special Rapporteur on the right to health, Anand Grover, explicitly 
cautioned against the inclusion of TRIPS-plus provisions in international trade and investment treaties, 
emphasizing that such agreements “have had an adverse impact on prices and availability of medicines, 
making it difficult for countries to comply with their obligations to respect, protect, and fulfil the right to 
health.”75 The Special Rapporteur recommended that developing countries and LDCs “not introduce TRIPS-
plus standards in their national laws” and that developed countries “not encourage developing countries 
and LDCs to enter into TRIPS-plus FTAs and … be mindful of actions which may infringe upon the right 
69 Recommendation 2.6.1(a) from the High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-
Level Panel on Access to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016). 
70 UNITAID, Area for Intervention Related to Intellectual Property: Supporting the Use of TRIPS Flexibilities (Geneva: UNITAID, December 13-14, 
2016), http://www.unitaid.eu/images/Resolutions/eb26/UNITAID_EB26_2016_R5_IP%20AfI.pdf. 
71 Charles T. Collins-Chase, “The Case against TRIPS-Plus Protection in Developing Countries Facing Aids Epidemics,” University of Pennsylvania 
Journal of International Law 29/763 (2014), http://scholarship.law.upenn.edu/jil/vol29/iss3/6.
72 See Box 8 of the Final Report of the High-Level Panel for a comprehensive summary of all the TRIPS-plus provisions found in existing free 
trade agreements. See High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on 
Access to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016).   
73 Ibid.
74 WHO, Essential Medicines and Health Products Information Portal: A World Health Organization Resource, Implications of the Doha Declaration on 
the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012, http://apps.who.int/medicinedocs/en/d/Js2301e/9.html. 
75 Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental 
Health (2009), Human Rights Council, Eleventh Session, March 31, 2009, UN Document No. A/HRC/11/12, https://documents-dds-ny.un.org/
doc/UNDOC/GEN/G09/127/11/PDF/G0912711.pdf?OpenElement [accessed April 27, 2017]. 
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to health.”76 The UN Secretary General’s High-Level Panel on Access to Medicines echoed these calls, 
recommending that “[g]overnments engaged in bilateral and regional trade and investment treaties should 
ensure that these agreements do not include provisions that interfere with their obligations to fulfil the right 
to health” and that governments conduct public health impact assessments prior to entering into such 
agreements.77
Research and Development 
The current innovation model primarily relies on market monopolies and high prices to fund research and 
develop new medicines. Describing the “prevailing model,” the aforementioned UNHLP report summarized:
 “[T]he biomedical industry, with the help of well-established intellectual property 
protection mechanisms, test data exclusivity, and significant public funding of 
research, invests in R&D, obtains marketing approval and pays for related expenses 
by charging prices that allow them to recover these substantial costs and generate a 
profit. Shareholders who invest in biomedical companies do so with the expectation 
of generating a return on investment.”78
 This model results in several perverse incentives for R&D and prioritizes the development of treatments for 
profitable diseases affecting the affluent while often neglecting the needs of the poor and marginalized who 
are unable to pay high end-product prices. The effects of the R&D model are also felt globally and regardless 
of socioeconomic status. For instance, antimicrobial resistance (AMR) represents a growing global health 
threat, and yet, since the development of effective antibiotics is both expensive and unprofitable, the market-
driven R&D system has little incentive to respond. The existing drug development paradigm requires high 
levels of antibiotic use in order to recover the costs of R&D, but mitigating the spread of antimicrobial 
resistance demands just the opposite: severe restrictions on distribution and use.79 As a result, R&D remains 
woefully inadequate and special intervention by governments, international organizations, the private sector, 
philanthropic organizations, and civil society are needed.80 It is estimated that by 2050, failing to tackle AMR 
may cost 10 million premature deaths per year and $100 trillion in cumulative economic damage.81
The dearth of effective treatments for neglected tropical diseases is also a key example of the failings of the 
existing drug development paradigm. Buruli ulcer, for example, is a painful infection that affects over 30 
countries. Combined antibiotics can treat the disease, but more innovative research is needed to develop 
an oral therapy to help scale-up effective disease control in poor settings.82 In this way, a profit-driven R&D 
model runs counter to the right of everyone to the highest attainable standard of health. According to 
the Office of the United Nations High Commissioner for Human Rights (OHCHR), drug companies bear 
a responsibility to invest in research and development for neglected diseases through in-house R&D or 
support for external research.  
76 Ibid. 
77 Recommendation 2.6.1(e) of the Final Report of the High-Level Panel on Access to Medicines. 
78 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 29.
79 C. Clift et al., Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales. Report from Chatham House Working 
Group on New Antibiotic Business Models (2015), Chatham House, https://www.chathamhouse.org/sites/files/chathamhouse/field/field_
document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf [accessed April 26, 2017]. 
80 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 29.
81 C. Clift et al., Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales. Report from Chatham House Working 
Group on New Antibiotic Business Models (2015), Chatham House, https://www.chathamhouse.org/sites/files/chathamhouse/field/field_
document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf [Accessed 26 April 2017].
82 WHO, Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap for Implementation (Geneva: WHO, 2012), 
      http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf 
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Currently, the fear of damaging a medicine’s market share often discourages pharmaceutical companies 
from disseminating important information about new medicines. As a result, there is little transparency of 
research data and methods of drug development. This practice poses not only a health risk for medicines 
users, but it is also counterintuitive to the knowledge sharing and creative process needed to develop 
new drugs. Furthermore, limited information sharing effectively restricts oversight of drug research and 
knowledge exchange that will ultimately delay drug innovation. As stated in OHCHR’s Human Rights 
Guidelines for Pharmaceutical Companies, “The right to the highest attainable standard of health not only 
requires that existing medicines are accessible, but also that much-needed new medicines are developed as 
soon as possible. [emphasis added]”83 In contrast to current practice, knowledge sharing is key to protecting 
patients from potentially harmful treatments and successfully developing new medicines. 
Ultimately, the current model of innovation delivers inaccessible medicines at prices that have become 
unaffordable for low-, middle-, and high-income countries alike. The field of cancer care is one example 
of the need for effective and affordable treatments across the globe, including in low- and middle-income 
countries where cancer rates are on the rise.84 A vial of trastuzumab (Herceptin®), a medicine for breast 
cancer recently added to the WHO Essential Medicines List, reportedly costs 15 times the per capita monthly 
income in India (2014);85 meanwhile, it runs up to 50,000 UK pounds to treat one patient for a year (2012).86 
Some companies justify these exorbitant prices by asserting they are warranted by heavy research and 
development costs. However, this argument fails to consider the many breakthrough essential medicines 
that were developed with government (tax-based) funding and/or in public-funded laboratories.87 In these 
cases where the fruits of drug development are patented and privately licensed, the public effectively pays 
twice: first to subsidize medical research, and again, to access the new medicine.
Contrary to the notion of the universality of the right to health, the CEO of pharmaceutical firm Bayer criticized 
India’s compulsory license for the cancer drug sorafenib (Nexavar®): “We did not develop this medicine 
for Indians. We developed it for Western patients who can afford it.”88 This business model becomes all the 
more egregious considering “5 percent of global resources for cancer are spent in the developing world, yet 
these countries account for almost 80 percent of disability-adjusted years of life lost to cancer globally.”89 
Addressing this paradox, Paul Farmer, co-founder of Partners in Health, has observed, “The market fails 
when it comes to research and development of drugs for the poor.”90 
Several innovative solutions for medicines R&D were tabled to the United Nations Secretary-General’s High 
Level Panel on Access to Medicines in 2016. The panel was tasked with assessing proposals to resolve the 
policy incoherencies between IP law and trade rules on the one hand, and human rights law and public health 
83 Office of the High Commissioner for Human Rights (OHCHR), Human Rights Guidelines for Pharmaceutical Companies in Relation to Access 
      to Medicines in General Assembly of the UN Special Rapporteur on the Right to the Highest Attainable Standard of Health, A/63/263 (August 11,  
2008), http://www.ifhhro.org/images/stories/ifhhro/documents_UN_special_rapporteur/3_4_8.pdf.
84 Ellen ‘t Hoen, Access to Cancer Treatment: A Study of Medicine Pricing Issues with Recommendations for Improving Access to Cancer Medication 
      (Oxford: Oxfam International, 2015), http://apps.who.int/medicinedocs/documents/s21758en/s21758en.pdf. 
85 Bloomberg News, “Roche Herceptin Copy’s Price Still Out of Reach in India,” January 20, 2014, http://www.bloomberg.com/news/ 
      articles/2014-01-20/roche-herceptin-copy-s-price-still-out-of-reach-in-india. 
86 The Telegraph, “Breast Cancer Sufferers Denied Two Drugs on NHS,” February 14, 2012, http://www.telegraph.co.uk/news/health
      news/9079213/Breast-cancer-sufferers-denied-two-drugs-on-NHS.html. 
87 Paul Farmer, Pathologies of Power: Health, Human Rights, and the New War on the Poor (see note 49). 
88 Knowledge Ecology International, Transcript of Bayer CEO Marjin Dekkers, quote at the December 3, 2013 FT Event, regarding India 
      compulsory license of Nexavar, http://keionline.org/node/1924.
89 A disability adjusted life year can be thought of as one lost year of healthy life. See Ellen ‘t Hoen, Access to Cancer Treatment: A Study of 
      Medicine Pricing Issues with Recommendations for Improving Access to Cancer Medication (Oxfam, May 2014), http://apps.who.int/medicinedocs/
      documents/s21758en/s21758en.pdf. 
90   Paul Farmer, Pathologies of Power: Health, Human Rights, and the New War on the Poor (see note 49), 305.
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needs on the other.91 Among the submissions they received was a proposal for an “Essential Medicines Patent 
Pool” that can allow for more affordable generics to be produced for communicable and non-communicable 
diseases while also remunerating patent holders.92 Another recommendation was to initiate a global treaty 
on biomedical R&D to allow governments to collectively pool funding, coordinate, and monitor research in a 
way that delinks the price of new medical products from research and development costs, thereby improving 
the affordability of health technologies.93 A radically new approach, “Health Innovation as a Public Good,” 
aims to “generate cheaper medicines for all public health needs” by shifting leadership, priority setting, 
and research financing to the public sector, which would result in public goods and eliminate the need for 
profit.94 These and other proposals were considered before the High Level Panel released its Final Report in 
September 2016. 
The Final Report provided a combination of high-level and highly specific recommendations for reform. 
With respect to TRIPS, the High Level Panel (HLP) reiterated existing calls for greater use of the public 
health flexibilities available under TRIPS but went slightly further; it cautioned governments and the private 
sector to refrain from threats, tactics, or strategies designed to undermine the use of TRIPS flexibilities 
by developing nations and recommended that any instances of undue pressure be reported to the WTO 
Secretariat during the Trade Policy Review of Member States and be met with punitive measures. 
With respect to research and development, the HLP recommended the negotiation of a binding R&D 
convention that would delink the costs of R&D from end product prices and redirect R&D to pressing public 
health needs, including neglected tropical diseases and antimicrobial resistance. 
With respect to global health governance, accountability, and transparency, the HLP recommended that 
(a) Member States improve institutional coherence between trade, IP and public health at the national 
level; (b) an independent review body and an inter-agency task force be developed by the UN Secretary-
General to assess progress on health technology innovation and access, and increase coherence between 
multilateral organizations, respectively; and (c) private biomedical companies report annually on actions 
taken to promote access to health technologies, and engage in transparent disclosure of the costs of R&D, 
marketing, and distribution, and any public funding received in the development of health technologies. 
The many, varied recommendations of the High Level Panel illustrate the complex challenges produced by 
the interaction between intellectual property, international trade, international human rights, and public 
health. Importantly, they demonstrate that the incoherencies between these spheres of influence can only 
be resolved using robust accountability frameworks that hold all stakeholders responsible for the impact of 
their actions on access to affordable health technologies.95 
V. Non-discrimination and equality
Access to medicines remains an illusory goal for traditionally marginalized groups. However, non-
discrimination and equality — two of the most fundamental principles under human rights law — is central 
91 United Nations Secretary-General’s High-Level Panel on Access to Medicines, “The Process” (website), http://www.unsgaccessmeds.org/
the-process/. 
92 Ellen ‘t Hoen, Brigit Toebes, Katrina Perehudoff, and Frederick Abbott, Submission to the UN High Level Panel on Access to Medicines 
by the Global Health Law Committee of the International Law Association, February 22, 2016, http://www.unsgaccessmeds.org/
inbox/2016/2/22/contributionglobal-health-law-committee-of-the-international-law-association. 
93 James Love and Judit Rius, Submission to the UN High Level Panel on Access to Medicines by Knowledge Ecology International, February 
29, 2016, http://www.unsgaccessmeds.org/inbox/2016/2/29/james-love. 
94 Els Torreele, Submission to the UN High Level Panel on Access to Medicines by Open Society Foundation, February 28, 2016, http://www.
unsgaccessmeds.org/inbox/2016/2/28/els-torreele. 
95 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016). 
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to the right to health.96  Under the ICESCR, access to medicines should be realized without distinction 
on the grounds of race, color, sex, language, religion, political or other opinion, national or social origin, 
property, disability, birth or other status.97 The International Convention on the Elimination of All Forms 
of Racial Discrimination also emphasizes that states must prohibit and eliminate racial discrimination in 
the enjoyment of public health and medical care.98 Failure to comply with these standards amounts to a 
violation of international law.99,100  
However, non-discrimination and equality do not always imply equal treatment.101 In some cases, states must 
assume positive obligations to prioritize underrepresented individuals and communities.102 For example, 
certain populations face particular health challenges, including higher mortality rates or barriers to access, 
that must be reflected in national health policies.103
People living with HIV and AIDS104
Navi Pillay, former UN High Commissioner for Human Rights, has stated, “The face of HIV has always 
been the face of our failure to protect human rights.” HIV/AIDS is a global epidemic. More than 30 million 
people have died of AIDS, and there are approximately 36.9 million people living with HIV today.105,106 Each 
year, some 2.5 million people become infected with HIV, and around 1.7 million people die of AIDS-related 
causes, mostly in low- and middle-income countries.107
HIV/AIDS disproportionately affects people living in developing countries and persons living in poverty. 
This distribution is deeply rooted in social, economic, and gender inequalities. Sub-Saharan Africa remains 
the worst-affected region, with 69% of all persons living with HIV/AIDS.108 The Caribbean region has the 
highest HIV prevalence outside of sub-Saharan Africa, and the number of new HIV infections is increasing 
in Eastern Europe, Central Asia, North Africa, the Middle East, and parts of Asia and the Pacific.109
HIV is treated with antiretroviral (ARV) therapy, which is a combination formula of at least three antiretroviral 
drugs that maximally suppress the HIV virus and halt the progression of the HIV disease.110 ARV therapy is 
effective both as life-saving treatment and as protection against HIV/ AIDS. However, coverage for people 
living with HIV/AIDS remains unequal, and in 2011, just 54% of people indicated for ARV in low- and middle-
income countries received the treatment. Globally, just 28% of children in need of treatment received ARV.111 
96 OHCHR and World Health Organization, The Right to Health, Fact Sheet No. 31, http://www.ohchr.org/Documents/Publications/   
       Factsheet31.pdf. 
97 Ibid. 
98 Ibid. 
99 Alicia Ely Yamin, “Not Just a Tragedy: Access to Medications as a Right under International Law,” Boston University International Law Journal 
       21/2, 325-371, http://www.bu.edu/law/journals-archive/international/volume21n2/325-372.pdf.pdf. 
100   See, e.g., Human Rights and Intellectual Property, U.N. Comm. on Econ., Soc. & Cultural Rts., 27th Sess.12, U.N Doc. E/C.12/2001/15
       (2001).
101 Paul Hunt and Rajat Khosla, “The Human Right to Medicines,” Sur: International Journal on Human Rights 8 (2008), 99-114.
102 Ibid.
103 OHCHR and World Health Organization, The Right to Health, Fact Sheet No. 31, http://www.ohchr.org/Documents/Publications/
        Factsheet31.pdf.
104 World Health Organization, Bulletin of the World Health Organization, “Access to AIDS Medicines Stumbles on Trade Rules,” http://www.
        who.int/bulletin/volumes/84/5/news10506/en/. 
105 UN General Assembly, Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS, A/RES/65/277 (June 10, 2011), www.
       unaids.org/en/media/unaids/contentassets/documents/document/2011/06/20110610_UN_A-RES-65-277_en.pdf.
106 WHO, HIV/AIDS Fact Sheet (updated November 2015), http://www.who.int/mediacentre/factsheets/fs360/en/. 
107 UNAIDS, Global AIDS Epidemic Facts and Figures (July 18, 2012), www.unaids.org/en/media/unaids/contentassets/documents/
        epidemiology/2012/201207_FactSheet_Global_en.pdf.
108 UNAIDS, Report on the Global AIDS Epidemic 2012 (2012), www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/
        gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf, 8-12. 
109 Ibid. 
110 WHO, “HIV/AIDS: Antiretroviral Therapy,” www.who.int/hiv/topics/treatment/en/.
111 Ibid.
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Although there is not yet universal access in many countries, treatment has been successful in extending 
life expectancy, decreasing HIV transmission, and promoting community activism and empowerment 
around HIV/AIDS and the protection of human rights. According to the Global Commission on HIV and 
the Law, “Legal strategies, together with global advocacy and generic [drugs], resulted in a 22-fold increase 
in ART access between 2001 and 2010.” These legal strategies included framing lack of access to ARV as a 
breach of human rights. Civil society action, such as that of the Treatment Action Campaign in South Africa, 
held national governments accountable to their legal obligations in international law and their domestic 
constitutions. These strategies can be replicated to access treatment for other epidemics.
A number of mechanisms are also available to help make HIV medicines more affordable. These include 
robust generic competition, local production, voluntary licensing by innovator to generic companies, and 
the use of flexibilities in the international trade and intellectual property rules (through the TRIPS Agreement 
and other WTO mechanisms) to achieve wider access to affordable generic medicines. One such flexibility 
is compulsory licensing, which is permitted by TRIPS Article 31. Under a compulsory license, the issuing 
government sets the terms upon which a third party can exploit a patented product without the patent 
holder’s consent. The patent holder receives adequate remuneration and retains exclusive rights over 
the patented good, except with respect to the compulsory licensee. Compulsory licenses have been an 
integral component of patent law for centuries, and have been used extensively by countries around the 
world.112 Canada’s highly permissive compulsory licensing regime facilitated significant price reductions 
in pharmaceutical drugs,113 and helped to establish a robust generic manufacturing industry before it was 
dismantled by NAFTA in the early 1990s.114 Since the start of the 21st century, a number of developing 
countries have either issued or threatened to issue compulsory licences on pharmaceutical products to 
expand access to affordable medicines, including Thailand, Brazil, Rwanda, Indonesia, Malaysia, Zambia, 
Zimbabwe, and Mozambique.115
There are numerous advantages associated with compulsory licensing for pharmaceutical drugs, including, 
inter alia, the ability to achieve significant price reductions long before the expiry of the patent term; the 
reduction in dependence on a sole supplier; and the ability to respond swiftly to public health emergencies. In 
2015, South Africa experienced severe shortages of Lopinavir/ritonavir (LPV/r), a combination antiretroviral 
medicine used in first-line ARV regimens for paediatric patients, and second-line regimens for adults and 
adolescents who have developed resistance to first-line treatments. The drug is marketed as “Aluvia” by 
patent holder AbbVie, which is the sole supplier in South Africa.116 The shortages resulted from AbbVie’s 
inability to deliver adequate supplies, and resulted in significant treatment disruptions for HIV patients. 
Treatment disruptions place HIV patients at risk of developing drug resistance and immunological failure. 
Patients who develop resistance to second-line treatment must be switched to third-line treatment, which is 
six times more expensive.117 Although generic versions of Aluvia were already prequalified by the World Health 
Organization, they could not be produced in, or imported into, South Africa until the expiry of AbbVie’s 
patent in 2028.118 The shortages triggered significant public outcry, and civil society organizations called 
112 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
        Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016).  
113 T. Fulda and P. Dickens, “Controlling the Cost of Drugs: The Canadian Experience,” Health Care Financing Review 1/2 (1979), 55-64.
114 J. Reichman, “Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options,” Journal of Law and Medical Ethics 37/2
       (2009), 247–263.
115 Ibid.
116   Health24, “Red flag over HIV Medicine Stockout,” Health24, October 28, 2015, http://www.health24.com/Medical/HIV-AIDS/Living-with
       HIV/Red-flag-over-HIV-medicine-stock-out-20151027 [accessed January 29, 2017].
117 Fix The Patent Laws! “A Timeline of Intellectual Property Reform in South Africa: 1994-2016,” http://www.fixthepatentlaws.org/wp-
       content/uploads/2016/09/IP-reform-timeline-for-email.pdf [accessed  January 9, 2017].
118 Health24, “Red flag over HIV Medicine Stockout,” Health24, October 28, 2015, http://www.health24.com/Medical/HIV-AIDS/Living-with-
       HIV/Red-flag-over-HIV-medicine-stock-out-20151027 [accessed January 29, 2017]. 
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for the South African government to issue a compulsory license on Aluvia.119 No such license was issued. 
Cases like these have prompted widespread calls for governments to “adopt and implement legislation that 
facilitates the issuance of compulsory licenses. Such legislation must be designed to effectuate quick, fair, 
predictable, and implementable compulsory licenses for legitimate public health needs, and particularly 
with regards to essential medicines”.120 
As countries continue to confront new challenges in the fight against HIV/AIDS, compulsory licensing 
will continue to be a critical tool for sustainable access to affordable antiretroviral treatment. Namibia, for 
example, has one of the highest antiretroviral treatment (ART) coverage rates in sub-Saharan Africa (at 
90%) but the country is increasingly struggling to combat HIV drug resistance (HIVDR) which requires 
second-line ART regimens with long-term toxicity and higher annual costs. There are widespread concerns 
about the sustainability of Namibia’s ART program given its heavy reliance on donor funds. Accordingly, 
compulsory licensing is critically needed to maintain drug-supply continuity and facilitate the development 
of local pharmaceutical manufacturing capacity. 
Children
Every year, over eight million children under five years of age die, many from illnesses such as diarrhea, 
malaria, HIV/AIDS, tuberculosis and pneumonia.121  Children and young people are also among the worst 
affected by the HIV epidemic, in large part due to mother-to-child transmission and slow progress in the 
prevention, diagnosis, and treatment of HIV in children specifically. Due to interrelated biological and social 
reasons—contact with infected persons, being less than five years of age, and severe malnourishment—
children are also especially vulnerable to TB. Each year, there are approximately 500,000 new TB cases and 
up to 70,000 TB deaths among children.122
As a particularly vulnerable, and often silent, subset of the population, children face unique challenges 
that prohibit them from enjoying the right to health, including access to child-friendly drugs. For instance, 
although effective treatments have been developed for many of the major diseases that affect children, often 
pediatric versions of these treatments do not exist. Children require dosages that are reflective of their age, 
physical condition, and body weight.123 Though it is common for healthcare providers to split adult dosages 
into halves or quarters for children’s use, these makeshift tablets risk inaccurate dosing, thereby reducing 
the efficacy and/or safety of the treatment.124  
Adult sized medicines are also often unpalatable and difficult to digest for children. Oral solutions and 
syrups are more tolerable, and yet medications in these forms are usually unavailable, too expensive, or 
unsuitable for use in low-income settings. For diseases requiring several treatments per day—HIV/AIDS 
is one example—a fixed dosage combination approach is ideal. However, these combination pills are 
much more expensive than their adult counterparts.125  To address some of these gaps, pediatric ARV drug 
development projects have been initiated. Generic companies also have been able to develop formulations 
for children.
119 Ibid.
120 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
       Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016).  
121 WHO, “Make Medicines Child Size,” http://www.who.int/childmedicines/en/.  
122   WHO, “Childhood Tuberculosis,” www.who.int/tb/challenges/children/en/index.html.
123   WHO, “Make Medicines Child Size” (see note 121). 
124   Ibid. 
125 Ibid. 
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Prior to 2006, few strides had been made in the research and development of child-friendly medicines. The 
difficulty of administering clinical trials on children made advances even more difficult.126 However, in 2006, 
civil society organizations and governments began to partner in a quest to develop safer and better quality 
medicines specifically tailored to a child’s unique needs.127 Improvements have been slow but steady. For 
instance, in 2007 WHO launched a campaign to remove some of these barriers, publishing the WHO Model 
List for Essential Medicines for Children and launching a campaign to promote the use of child-friendly 
tablets. 
Women 
Women are particularly vulnerable to violations of their rights in seeking access to medicines, especially 
for sexual and reproductive health care services. For example, women in many developing countries face 
a shortage of prophylactic uterotonics, a drug that helps to prevent and treat Postpartum Haemorrhage 
(PPH). PPH, defined as a blood loss of 500 ml or more within 24 hours after birth, is the leading cause 
of maternal mortality globally.128 Without access to prophylactic uterotonics during the third stage of 
labor, scores of women in low-income countries suffer from long-term disability, contract severe maternal 
conditions associated with substantial blood loss, and/or die preventable deaths. It is therefore unsurprising 
that the provision of essential medicines for sexual and reproductive health is a “core” duty of the state in 
the CESCR’s General Comment 22 on the right to sexual and reproductive health.129
Women and girls who have been trafficked for prostitution are especially vulnerable to HIV/AIDS and 
sexually transmitted infections and require access to medicines on a non-discriminatory basis. In its General 
Recommendation on “Women and Health,” the Committee to Eliminate Discrimination Against Women 
(“CEDAW”) noted: 
“The issues of HIV/AIDS and other sexually transmitted diseases are central to the rights of women 
and adolescent girls to sexual health. Adolescent girls and women in many countries lack adequate 
access to information and services necessary to ensure sexual health. . . . States parties should 
ensure, without prejudice or discrimination, the right to sexual health information, education and 
services for all women and girls.”130
In some cases, discrimination against women in their pursuit of medicines can be blatant. For instance, 
as the chapter on patient care has noted, Human Rights Watch documented abuses committed by health 
personnel who had deliberately refused to give pain-relieving medication to women while in labor.131
The Special Rapporteur on the right to health states, “Stigma and discrimination against women from 
marginalized communities, including indigenous women, women with disabilities and women living with 
HIV/AIDS, have made women from these communities particularly vulnerable to such abuses.”132 Female 
patients from marginalized populations have the right to seek health care, and goods that promote health 
(i.e. medicines), in a manner that is non-discriminatory and respects their dignity.
126   Ibid. 
127 Ibid. 
128 World Health Organization, WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage (Geneva: WHO, 2012).
129 Committee on Economic, Social and Cultural Rights, General Comment No. 22, The Right to Sexual and
        Reproductive Health (article 12 of the International Covenant on Economic, Social and Cultural Rights), UN Doc. No. E/C.12/GC/22
        (2016).
130 Committee on the Elimination of Discrimination against Women, General Recommendation 24, Women and Health (Twentieth session, 
        1999), U.N. Doc. A/54/38 at 5 (1999), reprinted in Compilation of General Comments and General Recommendations Adopted by 
        Human Rights Treaty Bodies, U.N. Doc. HRI/GEN/1/Rev.6 at 271 (2003), https://www1.umn.edu/humanrts/gencomm/generl24.htm. 
131  Human Rights Watch, “Stop Making Excuses”: Accountability for Maternal Health Care in South Africa (HRW, August 2011), http://reliefweb.int/
        sites/reliefweb.int/files/resources/Full_Report_2004.pdf.
132  Ibid.
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More recently, the Zika epidemic highlighted the systemic discrimination suffered by women in exercising 
their right to health. Laws and policies in Zika-affected countries which significantly curtail female reproductive 
rights thereby violate the right to health and the right to life enjoyed by both mother and child, given the 
proven link between Zika infection and microcephaly. The UN High Commissioner for Human Rights, Zeid 
Ra’ad Al Hussein, has repeatedly called for the repeal of laws that restrict access to sexual and reproductive 
health services to ensure that women have the information, support and services they require to exercise 
their rights to determine whether and when they become pregnant.133
Prisoners/detained persons
The right to health in prison lies at the nexus of positive and negative rights in the sense that, having deprived 
prisoners of their liberty and their ability to provide for their own health, states bear a positive obligation 
to protect their right to life and their right to health. Prisoners and detained persons in most countries do 
not relinquish their rights when they enter the jail system. However, since they are in many ways dependent 
upon the prison system, this population often faces violations of their rights, including the right to access 
medicines. 134  Prison environments render their occupants more susceptible to certain diseases.
For example, although many prisoners living with HIV contracted their infections before imprisonment, the 
risk of infection while in prison is high due to high-risk sexual and other behaviors, like sharing needles. 
High-risk sexual behaviors, including unprotected sex and sexual violence, rape, and coercion, are common 
in prison and increase prisoners’ vulnerability to HIV. Unsafe drug injection, blood exchange, and the use of 
non-sterile needles/cutting instruments for tattooing are also common and increase HIV vulnerability. Poor 
prison conditions, including overcrowding, malnutrition, poor security, and lack of health facilities and staff, 
contribute to the spread of HIV and violate prisoners’ human rights. 
Some prisons create separate or alternative sections for HIV-positive prisoners, segregating them from the 
rest of the prison population. In parts of Russia, prisoners are tested for HIV and those who test positive 
are imprisoned together, but separated from the general prison population. Two states in the United States, 
Alabama and South Carolina, continue to segregate prisoners living with HIV. The American Civil Liberties 
Union and the AIDS Project recently filed a lawsuit calling the practice discriminatory.135 Their reports 
highlight additional human rights violations that are consequences of discriminatory segregation.136
In addition, prisoners are by definition not free individuals who can go to the pharmacy, and they are 
dependent on others to physically provide medicines. Prisoners also often have little or no means to finance 
medicines, so they must be funded by the prison system. Both of these obstacles routinely obstruct prisoners 
from realizing their right to access medicines. For instance, due to high costs, it has been documented that 
prison systems have withheld newer medications, including drugs for Hepatitis C, from patients in need. 
Several such cases have been documented in the United States, including in Rhode Island, Massachusetts, 
and Minnesota.137 
133 OHCHR, “Upholding Women’s Human Rights Essential to Zika Response,” press release, February 5, 2016, http://www.ohchr.org/EN/
       NewsEvents/Pages/DisplayNews.aspx?NewsID=17014#sthash.6qsPD6Me.dpuf> [accessed April 27, 2017.]
134   For a complete discussion on harm reduction and freedom from torture and cruel, inhuman, and degrading treatment, including in prisons, 
       see chapter 4 of this Resource Guide. Harvard FXB Center for Health and Human Rights/ Open Society Foundations, Harm Reduction and
       Human Rights (Boston: Harvard FXB/ OSF, 2013), https://www.hhrguide.org/2014/03/12/how-is-harm-reduction-a-human-rights-issue/.
135 For the copy of the legal documents, news reports, and blog posts on the case, please see American Civil Liberties Union, Henderson et al. 
       v. Thomas et al., www.aclu.org/hiv-aids-prisoners-rights/henderson-et-al-v-thomas-et-al.
136 Ibid.
137 Peter Loftus, “Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs” New York Times, June 11, 2015, http://blogs.wsj.com/
        pharmalot/2015/06/11/prisoners-sue-massachusetts-for-withholding-hepatitis-c-drugs/. 
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The prison population includes vulnerable groups with special needs, including prisoners with mental health 
care needs, elderly prisoners, and prisoners with terminal illness. These vulnerable populations may require 
special attention to ensure that their rights to health and life with dignity are realized.
Older persons
Older persons are a vulnerable group and more susceptible to issues related to non-communicable 
diseases (NCDs) and pain management control. NCDs, such as cancer, heart disease, and diabetes, affect 
many people—but especially older people. NCDs prevention and treatment can also demand a chronic 
(and expensive) course of medicine that may not be available or affordable for this population.138 Because 
government-funded medicines are often the only source of treatment for this population, many of these 
patients must pay out-of-pocket to access medicines for their chronic conditions. These sometimes 
catastrophic expenses can force older patients to have to choose between medicines they need and their 
financial stability.139 The problem becomes even more acute when one considers the new, expensive medicines 
with proven therapeutic value to treat cancer. This raises an ethical and economic dilemma for industrialised 
and developing countries alike of how to afford these high-cost, therapeutically-innovative medicines. 
In developing countries, the affordability and accessibility of chronic and/or expensive pharmaceuticals 
is especially limited, and in many cases, unaffordable medicines leave older people with pain control as 
the only viable treatment. However, opioids needed to control pain are subject to additional regulation 
that restricts their much-needed use. While the international drug control framework, which includes the 
Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations 
Convention on Illicit Traffic in Narcotic and Psychotropic Drugs, has been crafted to combat illicit drug 
markets, it is incoherent with obligations that derive from human rights law. The restrictive interpretation of 
the control mechanisms included in the international drug control treaties directly hinder states access to 
controlled substances for medical purposes.140
The United Nations Committee on Economic, Social and Cultural Rights states that, with regard to the 
realization of the right to health of older persons, “attention and care for chronically and terminally ill 
persons [is important], sparing them avoidable pain and enabling them to die with dignity.” Therefore, an 
important component of palliative care is access to essential drugs that alleviate pain. 
In 2007, the International Association for Hospice and Palliative Care (IAHPC), in collaboration with 26 
palliative care organizations, developed a list of essential medicines for palliative care.141 Of the 34 medications 
listed, just 14 were included in the WHO Model List (most recently updated in 2011), and morphine was 
the only strong opioid analgesic included. Oral morphine is particularly essential for palliative care because 
it provides an inexpensive option for pain management. However, especially in low- and middle- income 
countries, only opioid formulations that are more expensive or more difficult to use, such as injectable 
morphine, are available. 
138  Alexandra Cameron, M. Ewen, Dennis Ross-Degnan et al., “Medicine Prices, Availability, and Affordability in 36 Developing and Middle-
        Income Countries: A Secondary Analysis,” Lancet 373 (2009), 240–49, http://www.thelancet.com/journals/lancet/article/PIIS0140-
        6736(08)61762-6/abstract. 
139 Hans V. Hogerzeil, Jonathan Liberman, Veronika J. Wirtz et al., “Promotion of Access to Essential Medicines for Non-Communicable 
        Diseases: Practical Implications of the UN Political Declaration,” Lancet 381 (2013), 680-9,
        http://fieldresearch.msf.org/msf/bitstream/10144/279037/1/Hogerzeil%20-%20Promotion%20of%20access%20to%20essential%2
        medicines%20for%20Non-Communicable%20Diseases-Practical%20implications%20of%20the%20UN%20Political%20Declaration.pdf. 
140 M.E.C. Gispen, “A Human Rights View on Access to Controlled Substances for Medical Purposes under the International Drug Control 
        Framework,” European Journal of Pharmacology 16 (2013). 
141  International Association for Hospice and Palliative Care, IAHPC List of Essential Medicines for Palliative Care (2007), http://hospicecare.com/
        resources/palliative-care-essentials/iahpc-essential-medicines-for-palliative-care/.
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The high cost of these opioids hinders access to treatment. Meanwhile, the low profit margin from oral 
morphine is exacerbated by additional costs of unnecessarily burdensome regulatory requirements, which 
may further deter the pharmaceutical industry from supplying it.142
Persons living with neglected diseases143
Neglected diseases are diseases for which there is a lack of sufficient medical innovation, resulting 
in inadequate, ineffective, or non-existent means to prevent, diagnose and treat them. The lack of 
sufficient medical innovation is often caused by a lack of market incentives to invest in products that will 
predominantly be directed towards populations with little or no purchasing power.144 Examples include: 
leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, Chagas disease, malaria, leprosy, 
African trypanosomiasis, tuberculosis and dengue.145 
Neglected diseases are demonstrative of entrenched global inequities that perpetuate disparities in the 
enjoyment of the right to health between the rich and the poor. For example, although the situation has 
improved, drug development efforts have largely focused on diseases with a higher return than those that 
afflict predominantly poor populations.
Through international cooperation and research and development,146 states bear the responsibility to 
improve the underlying determinants of health that predispose certain populations to these diseases.147 
More immediately, governments and civil society must pressure pharmaceutical companies to produce 
medicines that address neglected diseases. For example, the African Union Commission has suggested 
these activities should include “giving large pharmaceutical firms incentives to investigate the diseases that 
affect Africa, instead of focusing on the diseases of rich countries.”148
Neglected diseases do not only suffer from lack of R&D funding. The patenting of basic scientific research 
tools, such as gene fragments, does not allow developing world scientists to benefit from accumulated 
research. Publishers often price their copyright journals beyond the means of the Global South, wherein 
scientists are denied the right to information and developing countries subsequently do not benefit from the 
right to scientific progress and research. 
What are rights-based interventions and practices in the area of 
access to medicines?
Operationalizing a human rights framework is an essential approach toward advancing access to medicines. 
This multi-pronged approach should involve participation and coordination between governments, 
philanthropic organizations, international entities, civil society groups, and the private sector. 
To start, programmatic reforms to increase access must be incorporated in national policies and programs, 
with special consideration for populations that routinely face access barriers, such as incarcerated persons, 
women, children, and those affected by diseases that can only be treated with high priced medicines. Equally, 
the prioritization of access to essential medicines must be reflected in new rights-based laws and licensing 
142  Pallum India, “The Morphine Manifesto” (2012), http://palliumindia.org/manifesto/ 
143  OHCHR and World Health Organization, The Right to Health, Fact Sheet No. 31, http://www.ohchr.org/Documents/Publications/
        Factsheet31.pdf.
144 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
        Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 5. 
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the products of medical research. In addition, states, especially in the Global South, should fully utilize the 
public health flexibilities available under TRIPS to address their country’s specific domestic health needs. 
A number of other mechanisms are available to help make medicines more affordable. Some of these 
methods include promoting generic competition, local production, and voluntary licensing by innovator to 
generic companies. Pharmaceutical companies should respect the right of states to use TRIPS flexibilities 
and refrain from pursuing stronger intellectual property protection than that is required by TRIPS. Initiatives 
to increase access to medicines must also bear in mind the principle of transparency, so that accountability 
frameworks can hold all stakeholders to account and better address the misalignment between the right to 
health, trade, intellectual property, and public health objectives.149
A human rights approach must also be supported by robust international assistance and cooperation, 
especially where public health objectives cannot be fulfilled immediately by the state.150 As part of the 
tripartite classification of obligations for all human rights, experts increasingly contend that the duty to fulfill 
rights suggests that developed countries have positive duties beyond borders.151 According to the CESCR, 
developed countries have a responsibility to contribute to countries in need, to “the maximum of [their] 
capacities,” in situations of emergency.152 The courts can also play an important role in enforcing the right to 
health. In fact, right-to-health litigation to advance access to medicines exemplifies, in very practical terms, 
how human rights can be used to force governments to act.
The strategies outlined below all strive to increase access to medicines for all. Some of these strategies are 
ongoing, and should continue or be scaled up. 
Official and non-governmental initiatives and international assistance
The right to health obliges states to advance access to medicines through international assistance and 
cooperation.153 To help meet these commitments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, 
an independent, multilateral financing entity, was conceived in 2002. The Global Fund directs resources to 
countries to support their response to HIV/AIDS, tuberculosis, and malaria and is the largest multilateral 
funder program that provides access to treatments those diseases.154 UNITAID, an international drug 
purchasing financing facility, has been another pioneering initiative. Through multilateral coordination and 
strategic market interventions, UNITAID creates and improves upon incentives for the pharmaceutical sector 
to better meet the world’s health needs.155 Finally, the United States President’s Emergency Plan for AIDS 
Relief, otherwise known as PEPFAR, is another health financing mechanism, which has been instrumental 
in curtailing the HIV/AIDS epidemic by supporting ART treatment for nearly 9.5 million people worldwide 
as of September 2015.156 
149 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
        Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 9. 
150 Brazilian International AIDS Association/ Global AIDS Policy Watch, “HIV and AIDS in the Mandate of the Special Rapporteur on the Right 
        to Health: Genealogies, Lessons Learned, Challenges that Remain,” December 10, 2014, http://abiainternacional.fw2.com.br/news/articles
        hiv-and-aids-genealogies-lessons-learnd-and-challenges/124. 
151 Sigrun Skogly, Beyond National Borders: States’ Human Rights Obligations in International Cooperation (Antwerp, Netherlands: Intersentia, 2006), 
       13, 30; W. Vandenhole, “EU Obligations for Development: Extraterritorial Obligations under the ICESCR,” in M. Salomon, A. Tostensen, and   
        W. Vandenhole (eds), Casting the Net Wider: Human Rights, Development and New Duty-Bearers (Antwerp, Netherlands: Intersentia, 2007); W.
        Vandenhole, “Is There a Legal Obligation to Cooperate Internationally for Development?” Convention of the Rights of the Child (CRC) — 
        Report to General Day of Discussion (July 27, 2007), http://www.crin.org/docs/Vandenhole%20International%20Cooperation.pdf, p. 1.
152  Committee on Economic, Social and Cultural Rights (see note 8), para. 40.
153 Skogly et al. (see note 151).
154 Sarah L. M. Davis, “Human Rights and the Global Fund to Fight AIDS, Tuberculosis, and Malaria,” Health and Human Rights 16/1 (July 2014), 
       http://www.hhrjournal.org/2014/07/01/human-rights-and-the-global-fund-to-fight-aids-tuberculosis-and-malaria/. 
155 Joo-Young Lee, A Human Rights Framework for Intellectual Property, Innovation and Access to Medicines (Farnham, England: Ashgate Publishing 
       Limited, 2015).
156 InterAction, “HIV/AIDS, PEPFAR, and the Global Fund,” https://www.interaction.org/choose-to-invest-2017/hivaids-pepfar-global-fund. 
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This concept, which describes a financing model characterized by the uncoupling of R&D costs and 
consumer prices for health technologies, is known as “delinkage.”157 A joint WTO, WIPO, WHO study 
described “delinkage” in the following terms: “One important concept that evolved from this discussion 
is the concept of delinking price of the final product from the costs of R&D. This concept is based on the 
fact that patents allow developers to recoup the costs and make profits by charging a price in excess of the 
costs of production. This way of financing R&D is viewed as constituting a barrier to access to medicines in 
countries where populations pay out of their own pockets for medicines and thus cannot afford to pay high 
prices. The principle of delinking is based on the premise that costs and risks associated with R&D should 
be rewarded, and incentives for R&D provided, other than through the price of the product.”158
As the world moves to curtail the spread of diseases beyond HIV/AIDS, primarily for diseases that are not 
incentivized by a robust market, innovation models should actively seek to “delink” R&D costs from the 
end price of products and share the burden of these costs on an international scale. As the 2016 UNHLP 
has stated, the current “patchwork” of public, private, and philanthropic funding is not sufficient enough to 
sustain long-term public health financing.159 New proposals have included using the WHO as a galvanizing 
force to “initiate international talks about priority setting and burden sharing of the cost of essential health 
R7D and set new rules to allow for financing of innovation while equitable access to those innovations 
is assure. This would initiate international implementation of delinkage.”160 A subsequent adoption of a 
new medical R&D framework could also include the following elements: “R&D priorities driven by health 
needs; Binding obligations of governments to invest in health R&D; Equitable distribution of contributions 
across countries; Measures to improve the regulatory environment and collaboration; Measure to ensure 
affordability of the end product; Access-maximising licensing practices to deal with IP issues; and Innovative 
approaches to incentivising R&D based on linkage principles.”161
Governance and flexibilities allowed under TRIPS
World Trade Organization (WTO) Members must make full use of TRIPS flexibilities to promote access to 
medicines. In accordance with Article 8 of the agreement, states may “adopt measures necessary to protect 
public health” as they “[formulate] or [amend] their laws and regulations.” States should also take advantage 
of “the policy space available in Article 27… by adopting and applying rigorous definitions of invention and 
patentability that are in the best interests of the public health of the country and its inhabitants.” 
Flexibilities must be explicitly incorporated into national policies and legislation. In particular, laws should 
be amended to promote compulsory licensing, permit parallel importation, 
promote pre-grant opposition, strengthen antitrust remedies for abuse of monopoly power, and strengthen 
patentability criteria to ensure that patents are only awarded “when genuine innovation has occurred.”162 
157 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
        to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com
       static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 5.
158 World Health Organization (WHO), World Intellectual Property Organization (WIPO) and World Trade Organization (WTO), Promoting Access to 
       Medical Technologies and Innovation: Intersections between Public Health, Intellectual Property and Trade (Geneva: WHO, 2012), https://www.wto
       org/english/res_e/booksp_e/pamtiwhowipowtoweb13_e.pdf in Ellen ’t Hoen, Private Patents and Public Health: Changing Intellectual Property 
       Rules for Access to Medicines (The Netherlands: Health Action International, 2016), 22.
159   High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
       Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 36.
160  Ellen ’t Hoen, Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The Netherlands: Health 
       Action International, 2016), 131.
161 Ibid., 132.
162 High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
        Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), 36.
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Pharmaceutical policy reform
As Ministers and senior public officials have suggested,163 pharmaceutical companies can and should 
exercise good corporate governance. They can do so by adopting the OHCHR’s Human Rights Guidelines for 
Pharmaceutical Companies, including:
“1) The company should adopt a human rights policy statement which expressly recognises the 
importance of human rights generally, and the right to the highest attainable standard of health in 
particular, in relation to the strategies, policies, programmes, projects and activities of the company; 
2) The company should integrate human rights, including the right to the highest attainable standard 
of health, into the strategies, policies, programmes, projects and activities of the company; 
3) The company should always comply with the national law of the State where it operates, as well 
as any relevant legislation of the State where it is domiciled; 
4) The company should refrain from any conduct that will or may encourage a State to act in a way 
that is inconsistent with its obligations arising from national and international human rights law, 
including the right to the highest attainable standard of health.”164
Pharmaceutical companies are responsible for investing in research and development to benefit all patients. 
In the realm of competition and pricing, companies can engage in fair market practices.165 For instance, 
in 2014, Gilead issued a voluntary license for sofosbuvir to generic producers, a treatment for Hepatitis 
C, which allows production and supply of generic SOF to 101 countries for this disease. Although this is 
a positive step for 101 nations, Gilead’s license still excludes countries where 73 million people with the 
Hepatitis C virus live. This move effectively leaves out 46% of HCV patients globally from an agreement 
that can deliver more affordable generic treatment and allows supply to other countries in the event that, for 
instance, a compulsory license is issued.166
Health systems strengthening
Access to medicines fundamentally depends upon well-functioning health systems. According to guidelines 
set out by the OHCHR, systems must be “integrated, responsive, and accessible.”167 Governments should 
scale up their investment in these systems, as well as scale up transparency and participatory priority-setting 
for drug spending. 
Governments should also erect strong regulatory systems to ensure medicines are safe, effective, and of 
assured quality. A well formulated and comprehensive National Medicines Policy (NMP), as laid out by 
WHO, can guide governments to set priorities for the national pharmaceutical sector that satisfy their 
human rights obligations.168 A national essential medicines list outlines the most clinically- and cost-
effective medicines for priority diseases. When used within a health system, a national essential medicines 
list can help limited drug budgets achieve the greatest public health impact. In line with the principle of 
163  OHCHR, Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines, http://www.ifhhro.org/images/stories/
        ifhhro/documents_UN_special_rapporteur/3_4_8.pdf.
164 Ibid.
165 Office of the United Nations High Commissioner for Human Rights, General Assembly of the UN Special Rapporteur on the right to the 
        highest attainable standard of health (UN document: A/63/263, dated 11 August 2008), para. 45.
166 hepCoalition.org, “Gilead’s License on Hepatitis C drugs, Sofosbuvir and Ledipasvir: A Fool’s Bargain: Myths and Facts,” http://www.
        hepcoalition.org/advocate/advocacy-tools/article/gilead-s-license-on-hepatitis-c. 
167 Office of the United Nations High Commissioner for Human Rights, General Assembly of the UN Special Rapporteur on the Right to the 
        Highest Attainable Standard of Health.
168 WHO, Medicines Policy, http://www.who.int/medicines/areas/policy/en/. 
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progressive realization, governments should continuously increase the public funding available for essential 
pharmaceuticals, especially considering many of the most marginalized populations either pay out of pocket 
or make do without these medicines. 
Claim health rights before domestic or regional courts
The courts can also play a role in promoting health rights, including addressing the affordability and 
accessibility of medicines.169 This intervention in particular shows, in very practical terms, how human rights 
can be used as a tool to force the government to act.
The claims of individuals or groups have been particularly efficacious when access to medicines is linked to 
a country’s constitutional right to health or human rights treaties (including the right to health) ratified by 
the government. For example, a study identified that state recognition of the right to health in international 
or domestic law created a supportive environment for cases in which access to essential medicines was 
claimed as a derivative of the right to health and thereby reinforcing the enforceability through domestic 
courts.170 
Two case studies at the end of this chapter, based in Kenya and Georgia respectively, highlight recent trends 
in litigation concerning access to medicines. Both examples indicate that support from non-governmental 
organizations can help shepherd the likelihood of success. Secondly, it might be inferred that judges are 
increasingly ruling in favor of the protection of patient’s rights over the enforcement of patents.171
Though an uptake in the amount of cases litigating the right to medicines in national courts has been 
documented, the extent that this movement has on the right to health as a whole has yet to be determined.172,173
169 Ole Frithjof Norheim and Bruce M. Wilson, “Health Rights Litigation and Access to Medicines: Priority Classification of Successful Cases 
        from Costa Rica’s Constitutional Chamber of the Supreme Court,” Health and Human Rights 16/2 (October 2014), http://www.hhrjournal.
        org/2014/10/02/health-rights-litigation-and-access-to-medicines-priority-classification-of-successful-cases-from-costa-ricas-constitutional
        chamber-of-the-supreme-court/. 
170 The majority of these cases were documented in Central and Latin America. Hans V. Hogerzeil, Melanie Samson, Jaume Vidal Casanovas, et 
        al., “Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable Through the Courts?” Lancet 368 (2006),
       305–11, http://www.who.int/medicines/news/Lancet_EssMedHumanRight.pdf. 
171 Stephen P. Marks, “Access to Essential Medicines as a Component of the Right to Health” in Health: A Human Rights Perspective, https://
       cdn1.sph.harvard.edu/wp-content/uploads/sites/580/2012/10/marks_access_to_essential_medecines-2009.pdf. 
172 Hans V. Hogerzeil, “Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable Through the Courts?” 
173 See generally, A. Yamin and S. Gloppen (eds), Litigating Health Rights: Can Courts Bring More Justice to Health? (Cambridge, MA: Harvard
       University Press, 2011).
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2. Which are the most relevant international 
     and regional human rights standards 
     related to access to medicines? 
How to read the tables
Tables A and B provide an overview of relevant international and regional human rights instruments stan-
dards in so far as they relate to the health of the LGBTI community. They provide a quick reference to the 
rights instruments and refer you to the relevant articles of each listed human right or fundamental freedom 
that will be addressed in this chapter.
From Table 1 on, each table is dedicated to examining a human right or fundamental freedom in detail as it 
applies to patient care. The tables are organized as follows: The tables are organized as follows:
Human right or fundamental freedom 
Examples of Human Rights Violations
Human rights standards UN treaty body interpretation
This section provides general comments issued by UN treaty bodies as well as recom-
mendations issued to States parties to the human right treaty. These provide guidance 
on how the treaty bodies expect countries to implement the human rights standards 
listed on the left.
Human rights standards Case law
This section lists case law from regional human rights courts only. There may be ex-
amples of case law at the country level, but these have not been included. Case law 
creates legal precedent that is binding upon the states under that court’s jurisdiction. 
Therefore it is important to know how the courts have interpreted the human rights 
standards as applied to a specific issue area.
Other interpretations: This section references other relevant interpretations of the issue.  
It includes interpretations by:
• UN Special Rapporteurs
• UN working groups
• International and regional organizations
The tables provide examples of human rights violations as well as legal standards and precedents that can 
be used to redress those violations. These tools can assist in framing common health or legal issues as 
human rights issues, and in approaching them with new intervention strategies. In determining whether 
any human rights standards or interpretations can be applied to your current work, consider what violations 
occur in country and whether any policies or current practices in your country contradict human rights stan-
dards or interpretations.
Human rights law is an evolving field, and existing legal standards and precedents do not directly address 
many human rights violations. Through ongoing documentation and advocacy, advocates can build a stron-
ger body of jurisprudence on human rights (in access to medicines.)
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Abbreviations
In the tables, we use the following abbreviations to refer to the nine treaties and their corresponding 
enforcement mechanisms:  Also cited are the former Commission on Human Rights (CHR) and 
various UN Special Rapporteurs (SR) and Working Groups (WG).
Treaty Enforcement Mechanism
Universal Declaration of Human Rights (UDHR) Not Applicable
International Covenant on Civil and Political Rights 
(ICCPR)
Human Rights Committee (HRC)
International Covenant on Economic, Social, and  
Cultural Rights (ICESCR)
Committee on Economic, Social and Cultural Rights (CESCR)
Convention on the Elimination of All Forms of Discrimi-
nation Against Women (CEDAW)
Committee on the Elimination of Discrimination Against Women 
(CEDAW Committee)
International Convention on the Elimination of All 
Forms of Racial Discrimination (ICERD)
Committee on the Elimination of Racial Discrimination (CERD)
Convention on the Rights of the Child (CRC) Committee on the Rights of the Child (CRC Committee)
African Charter on Human and Peoples’ Rights and 
Protocols (ACHPR)
African Commission on Human and Peoples’ Rights (ACHPR 
Commission)
[European] Convention for the Protection of Human 
Rights and Fundamental Freedoms (ECHR)
European Court of Human Rights (ECtHR)
1996 Revised European Social Charter (ESC) European Committee of Social Rights (ECSR)
American Convention on Human Rights (ACHR) Inter-American Court of Human Rights (IACHR)
American Declaration of the Rights and Duties of Man 
(ADRDM)
Inter-American Court of Human Rights (IACHR)
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UDHR ICCPR ICESCR CEDAW ICERD CRC
Life Art. 3 Art. 6(1) Art. 6(1)
Torture or Cruel,  
Inhuman or Degrading 
Treatment*









Art. 2(2), Art. 
3











Liberty and Security of 
Person
Art. 3 Art. 9 (I) Art. 5(b)








Expression and  
Information Art. 19 Art. 19
Art. 5(d)
(viii)
Art. 12,  
Art. 13, 
Art. 17
Enjoy Benefits of Scientific 
Progress











Art. 25(2) Art. 24
Art. 10(3), Art. 
12(2)(a)
Art.5(b) All
*See also Convention against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment, 
Article 2.
Table A: International Human Rights Instruments and 
Protected Rights and Fundamental Freedoms
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Table 1: Access to Medicines and the Right to Non-
Discrimination and Equality
Examples of Human Rights Violations
• Zimbabwean prisoners in Botswana are denied access to antiretroviral (ARV) therapy to control their HIV infection and 
reduce opportunistic maladies while HIV positive Botswanan prisoners in the same institution are supplied with treatment.
• The Venezuelan Ministry of Defence denied HIV positive soldiers access to ARVs. But when the soldiers brought the case 
before court, the court voluntarily extended its decision to provide ARVs all infected members of the army. Only through 
subsequent litigation was access to ARVs and laboratory tests extended to all people with HIV, including civilians and those 
not eligible under existing health programmes.
Human Rights Standards Treaty Body Interpretation
ICERD 5(e)(iv) States Parties undertake 
to prohibit and to eliminate racial 
discrimination in all its forms and to 
guarantee the right of everyone, without 
distinction as to race, colour, or national 
or ethnic origin, to equality before the 
law, notably in the enjoyment of the 
following rights:
(e) Economic, social and cultural rights, 
in particular:
(iv) The right to public health, medical 
care, social security and social services. 
ICESCR 2(2) The States Parties to 
the present Covenant undertake to 
guarantee that the rights enunciated in 
the present Covenants will be exercised 
without discrimination of any kind as 
to race, colour, sex, language, religion, 
political or other opinion, national or 
social origin, property, birth or other 
status.
ICESCR 12(1) The States Parties to the 
present Covenant recognize the right of 
everyone to the enjoyment of the highest 
attainable standard of physical and 
mental health. 
CESCR General Comment 20: In explaining “other status” under ICESCR 2(2), CESCR 
explains “Health status refers to a person’s physical or mental health. States parties 
should ensure that a person’s actual or perceived health status is not a barrier to 
realizing the rights under the Covenant. The protection of public health is often cited 
by States as a basis for restricting human rights in the context of a person’s health 
status. However, many such restrictions are discriminatory, for example, when HIV 
status is used as the basis for differential treatment with regard to access to education, 
employment, health care, travel, social security, housing and asylum. States parties 
should also adopt measures to address widespread stigmatisation of persons on the 
basis of their health status, such as mental illness, diseases such as leprosy and women 
who have suffered obstetric fistula, which often undermines the ability of individuals 
to enjoy fully their Covenant rights. Denial of access to health insurance on the basis 
of health status will amount to discrimination if no reasonable or objective criteria can 
justify such differentiation.” E/C.12/GC/20 (June 10, 2009). 
CESCR General Comment 14: “With respect to the right to health, equality of access to 
health care and health services has to be emphasized. States have a special obligation 
to provide those who do not have sufficient means with the necessary health insurance 
and health-care facilities, and to prevent any discrimination on internationally prohibited 
grounds in the provision of health care and health services, especially with respect to 
the core obligations of the right to health.” 
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Human Rights Standards Treaty Body Interpretation
CESCR General Comment No. 14 (14): Explaining that “health facilities, goods and 
services must be accessible to all [without discrimination], especially to the most 
vulnerable and marginalized sections of the population . . . .” The Committee stated 
that this included the health care access needs of “ethnic minorities and indigenous 
populations, women, children, adolescents, older persons, persons with disabilities 
and persons with HIV/AIDS.” 
CEDAW 12(1) States Parties shall take 
all appropriate measures to eliminate 
discrimination against women in the 
field of health care in order to ensure, on 
a basis of equality of men and women, 
access to health care services, including 
those related to family planning. 
CEDAW General Recommendation No. 24 (12) (Women and Health): Affirming 
that “access to health care, including reproductive health, is a basic right under the 
Convention on the Elimination of All Forms of Discrimination against Women” and 
that States must “eliminate discrimination against women in their access to health-
care services throughout the life cycle, particularly in the areas of family planning, 
pregnancy and confinement and during the post-natal period.”
Human Rights Standards Case Law
Constitution of Botswana 15: 
(1) Subject to the provisions of 
subsections (4), (5) and (7) of this 
section, no law shall make any provision 
that is discriminatory either of itself or in 
its effect. 
(2) Subject to the provisions of 
subsections (6), (7) and (8) of this 
section, no person shall be treated in a 
discriminatory manner by any person 
acting by virtue of any written law or in 
the performance of the functions of any 
public office or any public authority.
(3) In this section, the expression 
“discriminatory” means affording 
different treatment to different persons, 
attributable wholly or mainly to their 
respective descriptions by race, tribe, 
place of origin, political opinions, colour 
or creed whereby persons of one such 
description are subjected to disabilities 
or restrictions to which persons of 
another such description are not made 
subject or are accorded privileges or 
advantages which are not accorded to 
persons of another such description.
High Court of Botswana: Finding that the denial of Highly Active Antiretroviral therapy 
to non-citizen inmates due to a Presidential Directive stating that the State must provide 
“free treatment to non citizen prisoners suffering from ailments other than AIDS” was 
unconstitutional as it violated the right to life (Section 4), the right to freedom from 
torture (Section 7), and the right to non-discrimination (Section 15). Tapela & Ors. V. 
Attorney General and Ors. (MAHGB-000057-14), BWHC 1 (2014).
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Human Rights Standards Treaty Body Interpretation
Constitution of Argentina (No 
specified articles).
Supreme Court of Argentina: Court rules to protect the right of life, right of health, and 
right to avoid discrimination of HIV-positive man after being denied the independent 
continuation of insurance coverage after his job termination and after the company learns 
of his condition. V., W. J. v. Obra Social de empleados de Comercio y Actividades Civiles. 
V. 1389. XXXVIII (2004).
Constitution of the Oriental Republic 
of Uruguay 8: All persons are equal 
before the law, no other distinctions 
being recognized among them save 
those of talent and virtue.
Third Civil Appellate Court of Uruguay: Finding that the Ministry of Public Health’s 
failure to provide drug Cetuximab to colon cancer patient because it was not listed in the 
Therapeutic Drug Registry violated the principle of equality because it had been given to 
others in similar circumstances. Sentencia No. 03/2011.
Other Interpretations:
Convention (No. 169) Concerning Indigenous And Tribal Peoples In Independent Countries, ILO, Art. 7(2) (June 27, 1989): States 
parties should “ensure that adequate health services are made available to the [indigenous and tribal] peoples concerned.” 
Declaration Of Commitment Of HIV/AIDS: By 2003, enact, strengthen or enforce, as appropriate, legislation, regulations and other 
measures to eliminate all forms of discrimination against and to ensure the full enjoyment of all human rights and fundamental 
freedoms by people living with HIV/AIDS and members of vulnerable groups, in particular to ensure their access to…prevention, 
support and treatment. 
United Nations Declaration On The Rights Of Indigenous Peoples, Art. 24: (I) Indigenous peoples have the right to their traditional 
medicines and to maintain their health practices, including the conservation of their vital medicinal plants, animals and minerals. 
Indigenous individuals also have the right to access, without any discrimination, to all social and health services … (II) Indigenous 
individuals have an equal right to the enjoyment of the highest attainable standard of physical and mental health. States shall take 
the necessary steps with a view to achieving progressively the full realization of this right.
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Table 2: Access to Medicines and the Right to Life 
Examples of Human Rights Violations
• In government health facilities pregnant mothers can receive healthcare and medicines to deliver their babies. However, 
systematic shortages of critical medicines needed to control bleeding during and after childbirth can contribute to the 
needless death of new mothers.
Human Rights Standards Treaty Body Interpretation
ICESCR 12(1): “The States’ Parties to 
the present Covenant recognize the 
right of everyone to the enjoyment 
of the highest attainable standard 
of physical and mental health.” 
“The steps to be taken by the States 
Parties to the present Covenant to 
achieve the full realization of this 
right shall include those necessary 
for . . . The prevention, treatment 
and control of epidemic, endemic, 
occupational and other diseases.” 
CESCR General Comment 14: “With respect to the right to health, equality of access to 
health care and health services has to be emphasized. States have a special obligation 
to provide those who do not have sufficient means with the necessary health insurance 
and health-care facilities, and to prevent any discrimination on internationally prohibited 
grounds in the provision of health care and health services, especially with respect to the 
core obligations of the right to health.”
ICCPR 6(1): Every human being has 
the inherent right to life. This right 
shall be protected by law. No one 
shall be arbitrarily deprived of his life. 
HRC General Comment No. 6 (1 and 5): Explaining that the right to life “should not be 
interpreted narrowly” or “in a restrictive manner,” and its protection “requires that States 
adopt positive measures . . . to increase life expectancy.” 
CRC 6(2): “States Parties recognize 
that every child has the inherent right 
to life” and “States Parties shall en-
sure to the maximum extent possible 
the survival and development of the 
child.”
CRC: Expressing to Cote d’Ivoire that “[w]hile noting the existence of the National 
Programme for the Control of AIDS, Sexually Transmitted Infections and Tuberculosis, the 
establishment of a special Ministry on HIV/AIDS, and the setting up of a committee on 
HIV/AIDS orphans, the Committee remains extremely concerned at the alarmingly high 
incidence and increasing prevalence of HIV/AIDS amongst adults and children and the 
resulting large number of children orphaned by HIV/AIDS.” CRC/C/15/Add.155 (2001) 
Human Rights Standards Case Law
ECHR 2(1): Everyone’s right to 
life shall be protected by law. No 
one shall be deprived of his life 
intentionally save in the execution of 
a sentence of a court following his 
conviction of a crime for which this 
penalty is provided by law. 
ECtHR: Holding that “this provision for the right to life requires states not only to prevent 
intentional killing but also to take steps against unintentional loss.” Tavares v. France, 
16593/90 (September 12, 1991) (unreported), cited in Rebecca J. Cook & Bernard M. 
Dickens, Human Rights Dynamics of Abortion Law Reform, 25 HUM. RTS. Q. 1, 28 (2003). 
[AY]
ACHPR 4(1): Every person has the 
right to have his life respected. 
This right shall be protected by law 
and, in general, from the moment 
of conception. No one shall be 
arbitrarily deprived of his life.
IACHR: The Court found the Nigerian government responsible for violating and failing 
to protect “such provisions as the right to life (Art. 4), the right to health (Art. 16) and 
the right to economic, social and cultural development (Art. 22). By its violation of these 
rights, the Nigerian government trampled upon not only the explicitly protected rights 
but also upon the right to food implicitly guaranteed.” Social and Economic Rights Action 
Center v. Nigeria, 155/96  (October 13-27, 2001), para. 67.
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights © 2017 FXB Center for Health and Human Rights Health and Human Rights Resource Guide
Access to Medicines 
10.34
Human Rights Standards Case Law
ACHR 4: “Every person has the right 
to have his life respected. . . . No one 
shall be arbitrarily deprived of his 
life.”
IACHR: “The right to life must be examined in its relationship to the commitment of the 
State, established in article 1(1), to respect and guarantee the full exercise of every right 
recognized in the [American] Convention.” Mendes v. Brazil (April 13, 1999), para.101.
Constitution of Bolivia (of 1967) 
7: Every person has the following 
fundamental rights, in accordance 
with the laws which regulate their 
exercise: (a) to life, to health and 
social security.
Constitutional Tribunal: Finding a violation of the right to life (and health and social 
security) in the cessation by COSSMIL (the Military Social Security Corporation) to provide 
HIV patient with necessary medications that he was not able to afford on his own. The 
court extended a previous judgment covering the continued provision of medicines for 
those suffering chronic illnesses to those suffering from HIV/AIDS. Ana María Campero 
de Romero, Defensora del Pueblo v. Máximo García Bonilla, et al., General Manager of 
Health. Constitutional Judgment 26/2003-R.
Constitution of Colombia 49: Public 
health and environmental protection 
are public services for which the state 
is responsible. All individuals are 
guaranteed access to services that 
promote, protect, and rehabilitate 
public health.
The Colombian Constitutional Court established that “the right to health was enforceable 
when it was inextricably related to enabling a life of dignity – and not merely preventing 
imminent death” and on this doctrine has ordered antiretroviral and cancer medications, 
financing treatment abroad for acute leukemia, treatment of severe depression, post-
mastectomy breast implants, administration of growth hormones, and care for severe 
vision problems.
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Table 3: Access to medicines and the right to the highest 
attainable standard of health
Examples of Human Rights Violations
• Venezuelans living with HIV lack the financial means to purchase antiretroviral medicines and the Ministry of Health 
& Social Assistance failed to provide this medication, condemning HIV-positive patients to a life of continuous health 
deterioration.
• Kenya’s Anti-Counterfeit Act could be interpreted to preclude genuine generic antiretroviral therapy to more affordably treat 
HIV infections. By enacting this legislation, the government violated its duty to ensure people have access to the medicines 
they need to stay healthy. 
Human Rights Standards Treaty Body Interpretation
UDHR 25(1): Everyone has the right 
to a standard of living adequate 
for the health and well-being of 
himself and of his family, including … 
medical care.
ICESCR 12(1): The States Parties to 
the present Covenant recognize the 
right of everyone to the enjoyment 
of the highest attainable standard of 
physical and mental health.
CESCR General Comment 14: Affirming “[m]ore determinants of health are being taken 
into consideration, such as resource distribution and that “formerly unknown diseases, 
such as human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/
AIDS), and others that have become more widespread, such as cancer, as well as the rapid 
growth of the world population, have created new obstacles for the realization of the right 
to health which need to be taken into account.” Para. 10 (2000).
CESCR General Comment 14: Concerning economic accessibility (affordability): “health 
facilities, goods and services must be affordable for all. Payment for health-care services, 
as well as services related to the underlying determinants of health, has to be based on 
the principle of equity, ensuring that these services, whether privately or publicly provided, 
are affordable for all, including socially disadvantaged groups. Equity demands that poorer 
households should not be disproportionately burdened with health expenses as compared 
to richer households. Para. 12b (2000).
CESCR General Comment 14: On the right to prevention, treatment and control of diseases, 
affirming the importance of “goods and services” that are “scientifically and medically 
appropriate and of good quality. This requires, inter alia….scientifically approved and 
unexpired drugs.” “The control of diseases refers to… the implementation or enhancement 
of immunization programmes and other strategies of infectious disease control.” Para 
12.2c (2000).
CESCR General Comment 14: Indicating that access to “essential drugs, as defined by the 
WHO Action Programme on Essential Drugs” is part of the minimum core content of the 
right to health. Fourteen palliative care medications are currently on the WHO Essential 
Drug List. Para. 43, (2000). 
ADRDM 6: Every person has the 
right to the preservation of his health 
through sanitary and social measures 
relating to food, clothing, housing 
and medical care, to the extent 
permitted by public and community 
resources. 
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Human Rights Standards Case Law
Constitution of Argentina, and Article 
11 of the American Declaration 
of the Rights and Duties of Man, 
Article 25 of the UDHR, and Article 
12 of the ICESCR, all of which have 
attained constitutional legal status in 
Argentina.
Federal Administrative Court of Appeals of Argentina: Court ordered the government to 
complete an unfinalized project to produce and distribute the vaccine for the Argentine 
Hemorrhagic Fever in order to comply with its national and international obligations 
regarding the right of health. Viceconte, Mariela Cecilia v. Argentine Ministry of Health and 
Social Welfare. Case n° 31. 777/96 (1998).
Constitution of Brazil 196: Health is 
a right of all and a duty of the State 
and shall be guaranteed by means of 
social and economic policies aimed 
at reducing the risk of illness and 
other hazards and at the universal 
and equal access to actions and 
services for its promotion, protection 
and recovery.
Federal Supreme Court of Brazil: Finding that the federal and state governments were 
responsible for the provision and distribution of essential medicines to needy populations 
(including those with the inability to pay for the required medications and those suffering 
from HIV/AIDS), under the responsibility set out by the constitutional right to health.  State 
of Pernambuco v. Geni Lira de Sales. AI 676044/PE (2007).
Other Interpretations:
WHO 1946 Constitution: “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human 
being without distinction of race, religion, political belief, economic or social condition” and “Unequal development in different 
countries in the promotion of health and the control of disease, especially communicable disease, is a common danger.” [OHCRH 
website]
SR Health: However, many countries have failed to adapt their drug control systems to ensure adequate medication supply; those 
systems were often enacted before contemporary treatment methods for chronic pain and drug dependence were known or devised. 
That constitutes an ongoing infringement of the right to health, as the Committee on Economic, Social and Cultural Rights has 
elaborated that access to essential medicines is a minimum core obligation of the right, and States must comply immediately with 
this non-derogable obligation regardless of resource constraints. A/65/255 (August 6, 2010).
SR Health: “The failure to ensure access to controlled medications for pain and suffering threatens fundamental rights to health and 
to protection against cruel, inhuman and degrading treatment.” 
Banjul Charter, Art. 16: “Every individual shall have the right to enjoy the best attainable state of physical and mental health.” 
European Social Charter, Art. 11(3): Contracting parties should undertake “appropriate measures designed inter alia . . . to prevent as 
far as possible epidemic, endemic and other diseases.” 
European Social Charter, Art., 13(1): Contracting parties should undertake “to ensure that any person who is without adequate resources 
and who is unable to secure such resources . . . be granted adequate assistance, and, in case of sickness, the care necessitated by his 
condition.”
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights
Access to Medicines 
10.37
Table 4:  Access to Medicines and the Right to Enjoy the 
Benefits of Scientific Progress and its Applications
Examples of Human Rights Violations
• With one of the highest rates of hepatitis C infection in Europe, Romanians know all too well that the standard treatment 
has limitations and a variety of side effects. New hope came when the novel wonder drug, sofosbuvir (Sovaldi®) was hailed 
to virtually cure Hepatitis C. But with a price tag of $50,000 per 12 week treatment, it is far out of reach for the Romanian 
government and patients.   
• Several neglected tropical diseases (NTD) caused by parasites, such as lymphatic filariasis or chistosomiasis, can be 
stopped through preventative chemotherapy. Recently, targeted populations have benefited from chemotherapy, yet 
Indonesia, Nigeria, Ethiopia the Democratic Republic of Congo and Tanzania still have large populations in need of access 
to at least one NTD treatment.
Human Rights Standards Treaty Body Interpretation
UDHR 27(1) Everyone has the right 
freely to participate in the cultural 
life of the community, to enjoy 
the arts and to share in scientific 
advancement and its benefits.
ICESCR 15(1)(b) The States Parties 
to the present Covenant recognize 
the right of everyone… [t]o enjoy the 
benefits of scientific progress and its 
applications… 
Human Rights Standards Case Law
ICESCR 15: 1. The States Parties to 
the present Covenant recognize the 
right of everyone: (b) To enjoy the 
benefits of scientific progress and its 
applications. 
Constitutional Court of Venezuela: Finding that although there is no express right to benefit 
from scientific and technological advances in the Venezuelan Constitution, and citing to 
this right under the ICESCR, the denial of lack of access to HIV medicines and testing 
services by the Venezuelan Social Security Institute violated this right, as well as the right 
to life and the right to health. López, Glenda & Ors. v. Instituto Venezolano de los Seguros 
Sociales (IVSS). Expediente No. 00-1343, Sentencia No. 487 (2001).
Other Interpretations:
SR Cultural Rights (2012):  Para. 61. The Special Rapporteur notes that new incentives have been proposed to ensure innovation and 
access to medicines at affordable costs, in particular for those living in extreme poverty. Importantly, the WTO Doha Declaration 
on the TRIPS Agreement and public health explicitly recognizes that the TRIPS Agreement “can and should be interpreted and 
implemented in a manner supportive of WTO Members’ right to protect public health”, and reaffirmed the right to use the flexibilities 
included in the Agreement for this purpose. A/HRC/20/26 (2012). 
Statement of the Committee on Economic, Social and Cultural Rights (Committee on Economic, Social and Cultural Rights, Human 
Rights and Intellectual Property, 2001): [T]he Committee draws attention to the various intellectual property treaties administered 
by the World Intellectual Property Organization (WIPO), as well as the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (the TRIPS Agreement) of the World Trade Organization (WTO), which set out minimum standards for the protection and 
enforcement of intellectual property rights. Reference could also be made to relevant articles of other treaties, such as the 1992 
Convention on Biological Diversity…. [T]he Committee recalls previous statements it has made in which it emphasized that the 
realms of trade, finance and investment are in no way exempt from human rights principles and that “international organizations 
with specific responsibilities in those areas should play a positive and constructive role in relation to human rights.” E/C.12/2001/15 
(2001).
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Other Interpretations (Continued):
Protocol San Salvador 14(1b): The States Parties to this Protocol recognize the right of everyone… [t]o enjoy the benefits of scientific 
and technological progress. 
Access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria, Resolutions 2005/23, 2004/26, 
2003/29 & 2002/32 (UN Commission on Human Rights).
General Comment No. 17: The right of everyone to benefit from the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he is the author (art. 15 (1) (c)) (CESCR, 2006): States parties should ensure that their 
intellectual property regimes constitute no impediment of their ability to comply with their core obligations in relation to the right 
to health ... States thus have a duty to prevent that unreasonably high license fees or royalties for access to essential medicines … 
undermine the right ... of large segments of the population to health .... E/C.12/GC/17 (2006).
Political Declaration on HIV/AIDS (UN General Assembly, 2006): Para. 33. Emphasize the need for accelerated scale-up of collaborative 
activities on tuberculosis and HIV, in line with the Global Plan to Stop TB 2006–2015, and for investment in new drugs, diagnostics 
and vaccines that are appropriate for people with TB-HIV co-infection.
Abuja Call for Accelerated Action Towards Universal Access to HIV/AIDS, Tuberculosis and Malaria Services in Africa (African Union, 
2006): Research and Development. To promote and support research and development of microbicides, vaccines, diagnostics and 
treatment for HIV and AIDS, TB and malaria, including traditional medicine. Sp/Assembly/ATM/2 (I) Rev.3 (2006).
Doha Declaration on the TRIPS Agreement and Public Health (World Trade Organization, 2001): Para. 4. [T]he TRIPS Agreement does 
not and should not prevent members from taking measures to protect public health. Accordingly, while reiterating our commitment 
to the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and implemented in a manner supportive of 
WTO members’ right to protect public health and, in particular, to promote access to medicines for all. WT/MIN(01)/DEC/2 (2001).
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights
Access to Medicines 
10.39
Table 5:  Access to Medicines and the Rights of Children
Examples of Human Rights Violations
• Meningitis, an infectious disease that causes the lining around the brain and spinal cord to swell, was endemic in certain 
regions of Colombia. Children lacking immunity and living in impoverished conditions where the disease can rapidly spread 
are at higher risk of infection. The meningitis vaccine was priced beyond the means of the poor families residing in the 
affected areas and was not provided as part of the government’s standard nor extended immunisation programmes. 
• Most medicines are produced in sizes and dosages fit for adults. Child sized medicines adapted to their smaller weight 
and palate are lacking, especially for tuberculosis where tablets are notoriously large, bitter tasting and difficult to swallow. 
Carers may even have to crush or chop adult pills for children to use, with little certainty that young patients are receiving 
the correct dose.
Human Rights Standards Treaty Body Interpretation
ICESCR (12a): The steps to be 
taken by the States Parties to the 
present Covenant to achieve the full 
realization of this right shall include 
those necessary for:
(a) The provision for the reduction 
of the stillbirth-rate and of infant 
mortality and for the healthy 
development of the child.
CESCR, General Comment 14(14): “The provision for the reduction of the stillbirth rate 
and of infant mortality and for the healthy development of the child” (Art. 12.2 (a)) may 
be understood as requiring measures to improve child and maternal health, sexual and 
reproductive health services, including access to family planning, pre- and post-natal care, 
emergency obstetric services and access to information, as well as to resources necessary 
to act on that information. E/C.12/2000/4 (August 11, 2000).
CESCR, General Comment 14(52): Violations of the obligation to fulfill occur through the 
failure of States parties to take all necessary steps to ensure the realization of the right 
to health. Examples include the failure . . . to reduce infant and maternal mortality rates. 
E/C.12/2000/4 (August 11, 2000).
CESCR: Expressing concern over high maternal, infant and under-five mortality rates in 
Angola E/C.12/AGO/CO/3 (CESCR, 2009), para. 36; Democratic Republic of Congo E/C.12/
COD/CO/4 (CESCR, 2009) para. 34; Kenya E/C.12/KEN/CO/1 (CESCR, 2008) para. 32; and 
Morocco E/C.12/1/ADD.55 (CESCR, 2000), para. 29.
CESCR: Recommending that Benin “step up its efforts to prevent and halt killings of so-
called “witch children” by including provisions in criminal law to suppress this practice 
and organizing campaigns to heighten awareness of its criminal nature among local 
authorities, doctors, midwives and the population at large.” E/C.12/BEN/CO/2 (CESCR, 
2008), para. 40.
CRC 6 States Parties recognize that 
every child has the inherent right to 
life … States Parties shall ensure to 
the maximum extent possible the 
survival and development of the 
child. 
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Human Rights Standards Treaty Body Interpretation
CRC 24(1) States Parties recognize the 
right of the child to the enjoyment of the 
highest attainable standard of health 
and to facilities for the treatment of 
illness and rehabilitation of health. States 
Parties shall strive to ensure that no child 
is deprived of his or her right of access to 
such health care services. 
CRC, General Comment 15 (2013) on the right of the child to the enjoyment of the 
highest attainable standard of health (art. 24): States have an obligation to make 
all essential medicines on the World Health Organization Model Lists of Essential 
Medicines, including the list for children (in paediatric formulations where possible) 
available, accessible and affordable. 
CRC: Expressing concern to Portugal that “Infant mortality, under-5 mortality and 
child tuberculosis rates remain higher than the regional average, particularly in 
some northern rural areas, and are also too high in the Azores” and recommending 
that the State “[i]ncrease investment in public health care facilities, including invest-
ments by civil society” and “[e]nsure the equal access of all children to the highest 
attainable standard of health care in all areas of the country.” CRC/C/15/Add.162 
(2001).
CRC: Expressing concern to Uzbekistan “at the increasing number of children in-
fected with preventable diseases, such as Tuberculosis …” and recommending that 
the State “[c]ontinue its reform of the health sector and its efforts to strengthen the 
primary care centres and the preventive health services.” CRC/C/UZB/CO/2 (2006).
CRC: Expressing concern in Armenia about “the continuous growth in tuberculosis 
morbidity among children” and recommending that the government “[t]ake mea-
sures to reduce child and infant mortality rates and combat tuberculosis.” CRC/C/15/
Add.225 (2004).
CRC: Expressing concern Gabon that it continues “to be threatened by early child-
hood diseases such as … tuberculosis” and recommending that it “[r]einforce its ef-
forts to allocate appropriate resources and develop and implement comprehensive 
policies and programmes to improve the health situation of children, particularly 
in rural areas” and “[f]acilitate greater access to primary health service.” CRC/C/15/
Add.171 (2002).
CRC: Expressing concern to Uzbekistan at the “high incidence of infectious diseas-
es, such as tuberculosis, despite high rates of immunization” and recommending 
the State “[i]mplement the 2000 Amsterdam Declaration to Stop TB.” CRC/C/15/
Add.167 (2001).
CRC: Expressing concern to Ethiopia “at the high incidence of malaria and tuberculo-
sis and their effects upon children, at the fragile health infrastructure, limited health 
awareness among the public and the limited implementation of the 1993 Health Pol-
icy and the 1994 Social Policy” and urging the State to “ensure that access to primary 
health care services is increased, that national health infrastructure is strengthened 
and that public health education programmes are used to lower infant mortality 
rates and raise life expectancy in the State party.” CRC/C/15/Add.144 (2001).
CRC: Expressing concern to Lithuania “at the high rates of child morbidity, in partic-
ular the increase in cases of tuberculosis” and recommending that the State “allo-
cate appropriate resources and develop comprehensive policies and programmes to 
improve the health situation of all children.” CRC/C/15/Add.146 (2001).
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Human Rights Standards Treaty Body Interpretation
CRC: Noting that Mauritania has a “resurgence of tuberculosis” and recommending 
that the State “[a]llocate appropriate resources and develop comprehensive policies 
and programmes to improve the health situation of all children without discrimination, 
in particular by focusing more on primary care and further decentralizing the health 
care system.” CRC/C/15/ADD.159 (2001).
CRC: Noting that Moldova has a “high incidence of tuberculosis … in schoolchildren” 
and recommending that the State “[d]efine sustainable financing mechanisms for the 
health care system, including adequate salaries for child health care professionals, in 
order to ensure that all children, in particular children from the most vulnerable groups, 
have access to free basic health care of good quality.” CRC/C/15/Add.192 (2002).
Human Rights Standards Case Law
Constitution of Colombia: The following 
are basic rights of children: life, physical 
integrity, health and social security, a 
balanced diet, their name and citizenship, 
to have a family and not be separated 
from it, care and love, instruction 
and culture, recreation, and the free 
expression of their opinions. They 
will be protected against all forms of 
abandonment, physical or moral violence, 
imprisonment, sale, sexual abuse, work 
or economic exploitation, and dangerous 
work. They will also enjoy other rights 
upheld in the Constitution, the laws, and 
international treaties ratified by Colombia. 
Colombian Constitutional Court: Finding violations of the right to life, to health, and 
to social security of children in the failure of the government to provide free, available 
meningitis vaccinations to children in a low-income sector of Bogota. Case SU-225/98 
(1998).
Right to health, right to life, and rights 
of the child as expressed in international 
human rights treaties ratified by 
Argentina and considered to have 
constitutional legal status.
Supreme Court of Argentina: Holding that the National Bank of Antineoplastic Drugs 
halting the provision of free Neutromax 300 - a drug on which a child with severe bone 
marrow defect was entirely dependent - was unconstitutional and that the federal 
state had the duty to provide medicines because of its international and constitutional 
responsibilities. Campodónico de Beviacqua, Ana Carina v. Ministerio de Salud y 
Acción Social – Secretaría de Programas de Salud y Banco de Drogas Neoplásicas. C. 
823. XXXV (2000).
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Other Interpretations:
WHO Model List of Essential Medicines, Children (WHO, 2011). 
South Africa: The South African Court established that “[the children’s] needs are ‘most urgent’ and their inability to have access 
to Nevirapine profoundly affects their ability to enjoy all rights to which they are entitled. Their rights are ‘most in peril’ as a result 
of a policy that has been adopted and are most affected by a rigid and inflexible policy that excludes them from having access to 
Nevirapine.”
CRC, General Comment 3 (2003) (art. 25): The obligations of States parties under the Convention extend to ensuring that children 
have sustained and equal access to comprehensive treatment and care, including necessary HIV-related drugs . . . It is now widely 
recognized that comprehensive treatment and care includes anti-retroviral and other drugs, diagnostics and related technologies for 
the care of HIV/AIDS, related opportunistic infections and other conditions ....CRC/GC/2003/1 (2003). 
WHO Guidance on ethics of tuberculosis prevention, care and control (WHO, 2010): The obligation to provide access to TB services. 
Interventions should be gender-sensitive and address different types of vulnerabilities…. In addition, the needs of women, children, 
and people coinfected with HIV warrant special consideration. 
WHO Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency Update (WHO, 2008): Extensive 
discussion of TB prevention, treatment and care options for children. Select recommendations:
9.5 Children. …Anecdotal evidence suggests that adolescents are at high risk for poor treatment outcomes. Early diagnosis, strong 
social support, individual and family counselling and a close relationship with the medical provider may help to improve outcomes 
in this group.
WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children (WHO, 2006). Abuja Call 
for Accelerated Action Towards Universal Access to HIV/AIDS, Tuberculosis and Malaria Services in Africa (African Union, 2006): 
Protection of Human Rights. To continue promoting an enabling policy, legal and social environment that promotes human rights 
particularly for women, youth and children and ensure the protection of people infected and affected by HIV and AIDS, TB and 
Malaria…. 
Prevention, Treatment, Care and Support. To invest heavily in evidence-based prevention as the most cost-effective intervention with 
focus on young people, women, girls and other vulnerable groups.  Sp/Assembly/ATM/2 (I) Rev.3 (2006).
Patients’ Charter for Tuberculosis Care (World Care Council, 2006): Care. The right to free and equitable access to tuberculosis care, 
from diagnosis through treatment completion, regardless of resources, race, gender, age, language, legal status, religious beliefs, 
sexual orientation, culture, or having another illness.
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Table 6:  Access to Medicines and the Rights of Women
Examples of Human Rights Violations
• Incorrect information circulated in Colombia by the Attorney General about how contraception containing levonorgestrel 
functioned, suggesting it is akin to an abortifacient and consequently illegal in the country. Empowering women to control 
their reproduction and engage in family planning relies on access to accurate information about contraception.
Human Rights Standards Treaty Body Interpretation
CEDAW 12(1) States Parties shall take 
all appropriate measures to eliminate 
discrimination against women in the 
field of health care in order to ensure, on 
a basis of equality of men and women, 
access to health care services, including 
those related to family planning.
CEDAW: Recommending that Kyrgyzstan “strengthen measures to reduce … the spread 
of tuberculosis and other diseases among women.” CEDAW/C/KGZ/CO/3 (2008).
CEDAW: Expressing concern to the increase of tuberculosis among women to Estonia 
A/57/38(SUPP) (2002), Vietnam A/56/38(SUPP) (2001), and Lithuania A/55/38(SUPP) 
(2000).
CEDAW Committee General Recommendation No. 24 (18): explaining that “[t]he issues 
of HIV/AIDS and other sexually transmitted diseases are central to the rights of women 
and adolescent girls to sexual health. Adolescent girls and women in many countries 
lack adequate access to information and services necessary to ensure sexual health… 
States parties should ensure, without prejudice or discrimination, the right to sexual 
health information, education and services for all women and girls…” 
Human Rights Standards Case Law
Constitution of South Africa 27:  1. 
Everyone has the right to have access 
to – (a) health care services, including 
reproductive health care; . . . 2. The 
state must take reasonable legislative 
and other measures, within its available 
resources, to achieve the progressive 
realization of each of these rights.
Constitutional Court of South Africa: Holding that the Government’s restriction 
preventing the provision of the drug Nevirapine to prevent the transmission of 
HIV from mothers to infants during childbirth in public hospitals and clinics was 
unconstitutional. Additionally, it called for a reformulation of the policy that provided 
this medicine at certain pilot-sties to increase availability and to “meet the constitutional 
requirement of providing reasonable measures within available resources for the 
progressive realisation of the rights of such women and newborn children.” Minister 
of Health v. Treatment Action Campaign (No. 2). ZACC 15; 2002 (5) SA 721; 2002 (10) 
BCLR 1033.
Other Interpretations:
Declaration of Commitment of HIV/AIDS: By 2005, implement measures to increase capacities of women and adolescent girls to 
protect themselves from the risk of HIV infection, principally through the provision of health care and health services, including for 
sexual and reproductive health, and through prevention education that promotes gender equality within a culturally and gender-
sensitive framework. Beijing Platform for Action – Women and health: Women have the right to the enjoyment of the highest 
attainable standard of physical and mental health. The enjoyment of this right is vital to their life and well-being and their ability to 
participate in all areas of public and private life. 
UN Commission on the Status of Women (2011): Calls on Governments to integrate HIV prevention, voluntary counselling and 
voluntary testing of HIV into other health services, including sexual and reproductive health, family planning, maternity and 
tuberculosis services. Resolution 55/2 (2011).
Women’s health in prison: Action guidance and checklists to review current policies and practices (WHO, UNODC, 2011): Para. 1. 
The underlying importance of human rights should underpin all thinking and all policy development for all those in compulsory 
detention.
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Other Interpretations (Continued):
Para. 3. Key services to be provided should include… specialist health care, which is readily provided and adjusted to meet the needs 
of women, such as for… chronic health conditions, HIV and AIDS (including counselling and support), hepatitis, tuberculosis (TB) 
and other infectious diseases....
WHO Guidance on ethics of tuberculosis prevention, care and control (WHO, 2010): The obligation to provide access to TB services. 
Interventions should be gender-sensitive and address different types of vulnerabilities…. In addition, the needs of women, children, 
and people coinfected with HIV warrant special consideration.
Agreed Conclusions of the Commission on the Status of Women on the Critical Areas of Concern of the Beijing Platform for Action 
1996-2009 (UN DESA, 2010): Recommending that governments, the UN system and civil society undertake measures to: “[i]ncrease 
the preventive, as well as the therapeutic, measures against tuberculosis and malaria”; intensify “support of national efforts against 
HIV/AIDS, particularly in favour of women and young girls, including efforts to provide affordable antiretroviral drugs, diagnostics 
and drugs to treat tuberculosis and other opportunistic infections”; “incorporate gender perspectives and human rights in health-
sector policies and programmes”; and “recognize that the lack of economic empowerment and independence increased women’s 
vulnerability to a range of negative consequences, involving the risk of contracting HIV/AIDS, malaria, tuberculosis and other 
poverty-related diseases” ST/ESA/327 (2010).
Resolution WHA 62.15, Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis (WHO, 
2009):  Para. 4. Urging member states “to increase investment by countries and all partners substantially in operational research and 
research and development for new diagnostics, medicines and vaccines to prevent and manage tuberculosis including multidrug-
resistant and extensively drug-resistant tuberculosis”. Resolution WHA 62.15.
Beijing Call for Action on Tuberculosis control and patient care: together addressing the global MDR-TB and XDR-TB epidemic 
(WHO, 2009): Para. 1(i). …[S]upporting developing countries to establish manufacturing plants to produce combined preparations 
of anti-TB medicines … to ensure adequate drug supply for the prevention and control of M/XDR-TB.
WHO Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency Update (WHO, 2008):
Extensive discussion of TB prevention, treatment and care options for women. Select recommendations: 
9.2 Pregnancy. All female patients of childbearing age should be tested for pregnancy upon initial evaluation…. [B]irth control is 
strongly recommended for all non-pregnant women receiving therapy for DR-TB because of the potential consequences for both 
mother and fetus resulting from frequent and severe adverse drug reactions. Pregnant patients should be carefully evaluated, taking 
into consideration gestational age and severity of the DR-TB.
9.3 Breastfeeding. A woman who is breastfeeding and has active DR-TB should receive a full course of antituberculosis treatment.
11.2 Pretreatment screening and evaluation. Methods of avoiding pregnancy during treatment for women of childbearing age should 
be discussed.
SR Health (2006): Commenting in Uganda, “stigma related to tuberculosis can be greater for women: it may lead, inter alia, to 
ostracism, rejection and abandonment by family and friends, as well as loss of social and economic support”. E/CN.4/2006/48/
Add.2 (2006)
Patients’ Charter for Tuberculosis Care (World Care Council, 2006): Care. The right to free and equitable access to tuberculosis care, 
from diagnosis through treatment completion, regardless of resources, race, gender, age, language, legal status, religious beliefs, 
sexual orientation, culture, or having another illness.
Abuja Call for Accelerated Action Towards Universal Access to HIV/AIDS, Tuberculosis and Malaria Services in Africa (African Union, 
2006): Protection of Human Rights. To continue promoting an enabling policy, legal and social environment that promotes human 
rights particularly for women, youth and children and ensure the protection of people infected and affected by HIV and AIDS, TB 
and Malaria….Prevention, Treatment, Care and Support. To invest heavily in evidence-based prevention as the most cost-effective 
intervention with focus on young people, women, girls and other vulnerable groups.  Sp/Assembly/ATM/2 (I) Rev.3 (2006).
Gender and tuberculosis control: towards a strategy for research and action (WHO, 1999): Noting that research strategies are 
needed to “[d]evelop guidelines and tools for TB programmes to minimise gender disparities”.
Beijing Declaration and Platform for Action (UN, 1995):  89. Women have different and unequal access to and use of basic health 
resources, including primary health services for the prevention and treatment of … tuberculosis, among others.
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Table 7:  Access to Medicines and Freedom from Torture and 
Cruel, Inhuman, and Degrading Treatment
Examples of Human Rights Violations
• Suffering from a tuberculosis (TB) infection, a prisoner in custody of the Russian authorities was provided with an 
irregular supply of medicine in an inadequate dosage to treat his infection. Inappropriately treated TB infections can lead 
to significant health deteriorations and other opportunistic infections.
Human Rights Standards Treaty Body Interpretation
UDHR 5 No one shall be subjected to 
torture or to cruel, inhuman or degrading 
treatment or punishment. 
ICCPR 7 No one shall be subjected to 
torture or to cruel, inhuman or degrading 
treatment or punishment. In particular, 
no one shall be subjected without his 
free consent to medical or scientific 
experimentation.
ICCPR 10(1) All persons deprived of their 
liberty shall be treated with humanity and 
with respect for the inherent dignity of 
the human person
HRC: Article 10, paragraph 1, imposes on States parties a positive obligation towards 
persons who are particularly vulnerable because of their status as persons deprived 
of liberty, and complements for them the ban on torture or other cruel, inhuman or 
degrading treatment or punishment contained in article 7 of the Covenant. Thus, 
not only may persons deprived of their liberty not be subjected to treatment that is 
contrary to article 7, including medical or scientific experimentation, but neither may 
they be subjected to any hardship or constraint other than that resulting from the 
deprivation of liberty; respect for the dignity of such persons must be guaranteed 
under the same conditions as for that of free persons. HRI/GEN/1/Rev.9 (Vol. I) 
(1992). General Comment 21.
CRC 37(a) No child shall be subjected 
to torture or other cruel, inhuman or 
degrading treatment or punishment. 
Neither capital punishment nor life 
imprisonment without possibility of 
release shall be imposed for offences 
committed by persons  below eighteen 
years of age.
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Human Rights Standards Treaty Body Interpretations
CRC 39 States Parties shall take all 
appropriate measures to promote 
physical and psychological recovery and 
social reintegration of a child victim 
of: any form of neglect, exploitation, 
or abuse: torture or any other form of 
cruel, inhuman or degrading treatment 
or punishment; or armed conflicts. Such 
recovery and reintegration shall take 
place in an environment which fosters 
the health, self-respect and dignity of the 
child.
CRC, General Comment 8 (2006) on the right of the child to protection from corporal 
punishment and other cruel or degrading forms of punishment: “Corporal punish-
ment and other degrading forms of punishment may inflict serious damage to the 
physical, psychological and social development of children, requiring appropriate 
health and other care and treatment. This must take place in an environment that 
fosters the integral health, self-respect and dignity of the child, and be extended as 
appropriate to the child’s family group.” 
CRPD 15 No one shall be subjected to 
torture or to cruel, inhuman or degrading 
treatment or punishment. In particular, 
no one shall be subjected without 
his or her free consent to medical or 
scientific experimentation. 2. States 
Parties shall take all effective legislative, 
administrative, judicial or other measures 
to prevent persons with disabilities, on 
an equal basis with others, from being 
subjected to torture or cruel, inhuman or 
degrading treatment or punishment.
Human Rights Standards Case Law
ECHR 3: No one shall be subjected to 
torture or to inhuman or degrading 
treatment of punishment.
ECtHR: Holding that the provision of only two medicines to a prisoner requiring 
three different medicines for tuberculosis lead to “prolonged mental and physical 
suffering diminishing his human dignity,” and this amounted to inhuman and 
degrading treatment. Gladkiy v. Russia, App. No. 3242/03, Eur. Ct. H.R. (2010).  
ECHR 3: No one shall be subjected to 
torture or to inhuman or degrading 
treatment of punishment.
ECtHR: Finding that the removal of an HIV-positive St. Kitts national from the U.K. 
after imprisonment would amount to inhuman treatment as “his removal would 
expose him to a real risk of dying under most distressing circumstances”. The Court 
bases this decision on the exceptional circumstances of the critical stage of his 
illness and the impossibility of accessing the drugs needed for his treatment in St. 
Kitts. D v. United Kingdom, App. No. 30240/96, 24 Eur. H.R. Rep. 423 (1997).
United States Constitution, Amendment 
8: Excessive bail shall not be required, nor 
excessive fines imposed, nor cruel and 
unusual punishments inflicted.
11th Circuit Court of Appeals of the United States: Holding that stopping to prescribe 
medications to a prisoner suffering from HIV and hepatitis was a violation of the 
Eighth Amendment because of the seriousness of the medical needs of the patient, 
and the deliberate indifference to these needs by the doctors and the prison. Brown 
v. Johnson, 387 F.3d 1344 (2004).
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Other Interpretations
SR Torture and Other Cruel, Inhuman, or Degrading Treatment or Punishment “Ensuring the availability and accessibility of 
medications included in the WHO Model List of Essential Medicines is not just a reasonable step but a legal obligation under the 
Single Convention on Narcotic Drugs, 1961. When the failure of States to take positive steps, or to refrain from interfering with health-
care services, condemns patients to unnecessary suffering from pain, States not only fall foul of the right to health but may also 
violate an affirmative obligation under the prohibition of torture and ill-treatment (A/HCR/10/44 and Corr.1, para. 72). 
In a statement issued jointly with the Special Rapporteur on the right to health, the Special Rapporteur on the question of torture 
reaffirmed that the failure to ensure access to controlled medicines for the relief of pain and suffering threatens fundamental rights to 
health and to protection against cruel, inhuman and degrading treatment. Governments must guarantee essential medicines – which 
include, among others, opioid analgesics – as part of their minimum core obligations under the right to health, and take measures to 
protect people under their jurisdiction from inhuman and degrading treatment.” Para. 55 & 56 A/HRC/22/53 (2013)
Economic and Social Council: “The right to health contains both freedoms and entitlements. The freedoms include the right to 
control one’s health and body, including sexual and reproductive freedom, and the right to be free from interference, such as the right 
to be free from torture, non-consensual medical treatment and experimentation.” Para. 8 E/C/2000/4
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3. WHAT IS A HUMAN RIGHTS-BASED 
APPROACH TO ADVOCACY, LITIGATION, AND 
PROGRAMMING?
 
What is a human rights-based approach?
“Human rights are conceived as tools that allow people to live lives of dignity, to be free and equal citizens, to 
exercise meaningful choices, and to pursue their life plans.”1 
A human rights-based approach (HRBA) is a conceptual framework that can be applied to advocacy, 
litigation, and programming and is explicitly shaped by international human rights law. This approach can be 
integrated into a broad range of program areas, including health, education, law, governance, employment, 
and social and economic security. While there is no one definition or model of a HRBA, the United Nations 
has articulated several common principles to guide the mainstreaming of human rights into program and 
advocacy work:
1. The integration of human rights law and principles should be visible in all work, and the aim of all 
programs and activities should be to contribute directly to the realization of one or more human rights. 
2. Human rights principles include: “universality and inalienability; indivisibility; interdependence and 
interrelatedness; non-discrimination and equality; participation and inclusion; accountability and the 
rule of law.”2 They should inform all stages of programming and advocacy work, including assessment, 
design and planning, implementation, monitoring and evaluation.
3. Human rights principles should also be embodied in the processes of work to strengthen rights-related 
outcomes. Participation and transparency should be incorporated at all stages and all actors must be 
accountable for their participation.
A HRBA specifically calls for human rights to guide relationships between rights-holders (individuals and 
groups with rights) and the duty-bearers (actors with an obligation to fulfill those rights, such as States).3 
With respect to programming, this requires “[a]ssessment and analysis in order to identify the human rights 
claims of rights-holders and the corresponding human rights obligations of duty-bearers as well as the 
immediate, underlying, and structural causes of the non-realization of rights.”4 
A HRBA is intended to strengthen the capacities of rights-holders to claims their entitlements and to enable 
duty-bearers to meet their obligations, as defined by international human rights law. A HRBA also draws 
attention to marginalized, disadvantaged and excluded populations, ensuring that they are considered both 
rights-holders and duty-bearers, and endowing all populations with the ability to participate in the process 
and outcomes. 
What are key elements of a human rights-based approach?
Human rights standards and principles derived from international human rights instrument should guide 
the process and outcomes of advocacy and programming. The list below contains several principles and 
questions that may guide organisations in considering the strength and efficacy of human rights within their 
own programs or advocacy work. Together these principles form the acronym PANELS.
1  A. Yamin, “Will We Take Suffering Seriously? Reflections on What Applying a Human Rights Framework to Health Means and Why We 
Should Care,” Health and Human Rights 10/1 (2008).
2  For a brief explanation of these principles, see UN Development Group (UNDG), The Human Rights Based Approach to Development 
Cooperation towards a Common Understanding among UN Agencies (May 2003), . 
3  Ibid.
4  Ibid.
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1. Participation: Does the activity include participation by all stakeholders, including affected 
communities, civil society, and marginalized, disadvantaged or excluded groups? Is it situated in 
close proximity to its intended beneficiaries? Is participation both a means and a goal of the program?
2. Accountability: Does the activity identify both the entitlements of claim-holders and the obligations 
of duty-bearers? Does it create mechanisms of accountability for violations of rights? Are all actors 
involved held accountable for their actions? Are both outcomes and processes monitored and 
evaluated?
3. Non-discrimination: Does the activity identify who is most vulnerable, marginalized and excluded? 
Does it pay particular attention to the needs of vulnerable groups such as women, minorities, 
indigenous peoples, disabled persons and prisoners?
4. Empowerment: Does the activity give its rights-holders the power, capacity, and access to bring 
about a change in their own lives? Does it place them at the center of the process rather than treating 
them as objects of charity?
5. Linkage to rights: Does the activity define its objectives in terms of legally enforceable rights, with 
links to international, regional, and national laws? Does it address the full range of civil, political, 
economic, social, and cultural rights?
6. Sustainability: Is the development process of the activity locally owned? Does it aim to reduce 
disparity? Does it include both top-down and bottom-up approaches? Does it identify immediate, 
underlying and root causes of problems? Does it include measurable goals and targets? Does it 
develop and strengthen strategic partnerships among stakeholders?
Why use a human rights-based approach?
There are many benefits to using a human rights-based approach to programming, litigation and advocacy. 
It lends legitimacy to the activity because a HRBA is based upon international law and accepted globally.  A 
HRBA highlights marginalized and vulnerable populations.  A HRBA is effective in reinforcing both human 
rights and public health objectives, particularly with respect to highly stigmatizing health issues.5 Other 
benefits to implementing a human rights-based approach include: 
1. Participation: Increases and strengthens the participation of the local community.
2. Accountability: Improves transparency and accountability.
3. Non-discrimination: Reduces vulnerabilities by focusing on the most marginalized and excluded in 
society.
4. Empowerment: Capacity building.
5. Linkage to rights: Promotes the realization of human rights and greater impact on policy and practice.
6. Sustainability: Promotes sustainable results and sustained change.
How can a human rights-based approach be used?
A variety of human rights standards at the international and regional levels applies to patient care. These 
standards can be used for many purposes including to:
1. Document violations of the rights of patients and advocate for the cessation of these violations.
2. Name and shame governments into addressing issues.
3. Sue governments for violations of national human rights laws.
5  V. Gauri and S. Gloppen, Human Rights Based Approaches to Development: Concepts, Evidence, and Policy, World Bank Policy Research Working 
Paper 5938 (January 2012), http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-5938.
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4. File complaints with national, regional and international human rights bodies.
5. Use human rights for strategic organizational development and situational analysis.
6. Obtain recognition of the issue from non-governmental organizations, governments or
       international audiences. Recognition by the UN can offer credibility to an issue and move a 
       government to take that issue more seriously.
7. Form alliances with other activists and groups and develop networks.
8. Organize and mobilize communities. 
9. Develop media campaigns. 
10. Push for law reform. 
11. Develop guidelines and standards. 
12. Conduct human rights training and capacity building 
13. Integrate legal services into health care to increase access to justice and to provide holistic care. 
14. Integrate a human rights approach in health services delivery.
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4. What are some examples of effective human 
rights-based work in advancing access to 
medicines?
This section contains four examples of effective human rights-based work in the area of patient care and 
human rights. These are: 
1. Challenging the 2008 Anti-Counterfeit Act in Kenya
2. Litigating to increase access to HIV drugs in India 
3. Promoting TRIPS flexibilities to increase access to medicines in Uganda
4. Litigating for prisoners with Hepatitis C in Georgian prisons
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Founded in 1994 and formally registered in 2001, KELIN 
is a national NGO in Kenya that responds to human rights 
concerns relating to health, including access to medicines. 
AIDS Law Project Kenya (ALP) is a non-governmental 
organization that works to promote equal rights and justice 
for people living with HIV and AIDS. ALP employs legal 
strategies to advance health rights for people living with and 
affected by HIV and AIDS.6
Problem 
The 2008 Anti-Counterfeit Act posed a threat for people 
living with HIV/AIDS in their pursuit of life-saving medicines. 
By failing to distinguish between counterfeit goods and 
generic medicines, the Act threatened to limit the availability 
and affordability of ARVs in Kenya. Since 90% of Kenyan 
patients with HIV depend on generic drugs imported by the 
government and donors, the Act’s potential repercussions 
could have been tremendous. On the whole, the incidence of 
HIV in Kenya is especially high, particularly for women and 
children. According to the 2010 Country Report to the United 
Nations General Assembly Special Session on HIV and AIDS, 
the National Aids Control Council, citing the Kenya AIDS Indicators Survey (2007), 7.4% of the population 
aged 15-49 is infected with HIV. 8.4% of women are infected compared to 5.4% of men. The Kenya National 
HIV and AIDS Estimates (2010) reports that mother-to-child transmission of HIV/AIDS makes children 
especially at risk.7
Actions Taken
On June 8, 2009, the firm of Majanja Luseno & Company Advocates filed a case on behalf of three adults 
living with HIV/AIDS, bringing on a constitutional challenge to the High Court of Kenya (the “Anti-Counterfeit 
Case”). Patricia Asero, Maurine Murenga, and Joseph Munyi had been taking HIV drugs for the last ten 
years or so since generic antiretroviral (ARV) HIV drugs became widely available as a result of the 2001 
Industrial Property Act. The three applicants claimed that the Anti-Counterfeit Act of 2008 would deny them 
the opportunity to purchase generic drugs, substantially increasing the cost of HIV medication. AIDS Law 
Project Kenya (ALP) and the United Nations Special Rapporteur for Health, Anand Grover, were enjoined as 
interested parties to this case. KELIN provided research support to the lead advocate during the case.
6   The AIDS Law Project (ALP) is a non-governmental organization which works exclusively to promote equal rights and justice for people 
living with HIV and AIDS. See http://www.aidslawproject.org/about-aids-law-project/; see also http://www.ohchr.org/EN/Issues/Health/Pages/
SRRightHealthIndex.aspx, and http://www.ohchr.org/EN/Issues/Health/Pages/SRBio.aspx.
7   KELIN, Threat Posed by 2008 Anti-Counterfeit Act to Access Generic Medicines in Kenya (Kenya: KELIN, 2012), http://kelinkenya.org/wp-content/
uploads/2010/10/Anti-Counterfeit-Act-to-Access-Generic-Medicines-in-Kenya-booklet.pdf. 
“The Kenyan decision in the Anti-Counterfeit 
Case demonstrates that strategic litigation can 
be used to ensure that access to the right to 
health is realized. In order to succeed in these 
kind of cases, it is important to have a clear 
case strategy from the outset, and to seek 
partnerships with people or organizations who 
possess relevant expertise to enjoin in the case, 
as this will help to ensure that the court has 
all the relevant decisions to make an informed 
judgment. We are of the view that this case 
will provide a pivotal reference point during 
deliberations on the development of laws and 
policies relating to anti-counterfeit goods at the 
East African regional level, and at the national 
level of each member state in East Africa which 
intends to pass laws similar to the Kenyan one.”
–Allan Maleche, Executive Director of 
KELIN, and Emma Day, Volunteer Lawyer 
at KELIN, “Right to Health Encompasses 
Right to Access Essential Generic Medicines: 
Challenging the 2008 Anti-Counterfeit Act 
in Kenya” in Health and Human Rights 16/2
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Arguing that the Act amounted to a violation of their rights to life, dignity, and health, Asero, Murenga, 
and Munyi urged the government to consider the Act again and re-draft it as it related to the definition of 
counterfeit medicine. More specifically, the petitioners claimed that the Act, as written in section 2, failed to 
exempt generic medicines from its definition of “counterfeit goods,” which was referred to as:
“manufacture, production…or making, whether in Kenya or elsewhere, of any goods 
whereby those protected goods are imitated in such manner and to such a degree 
that those other goods are identical or substantially similar copies of the protected 
goods.”8
By neglecting to outline a clear distinction between both terms, the Act had the potential to prohibit the 
importation and manufacture of generic medicines in Kenya. The Act also outweighed the positive effects of 
the Industrial Property Act (2001) which had allowed for parallel importation of medicines put legitimately 
on the market elsewhere, making generic drugs affordable and available in Kenya.
Asero, Murenga, and Munyi argued that the withholding of generic medications, which are taken daily for 
survival, constituted a violation of the right to life as guaranteed in the Kenyan Constitution (which came into 
force in 2010, after the case had been filed). The Act also directly conflicted with the 2006 HIV and AIDS 
Prevention and Control Act, which recognized the “special status” of persons living with HIV and AIDS and 
granted these persons “full protection of their human rights and civil liberties.” 
Later enjoined as an interested party, the United Nations Special Rapporteur for Health, Anand Grover, 
underscored that “legitimately produced” generic medicines had been conflated with goods that violate 
private intellectual rights. He emphasized that this conflation was “likely to have a serious adverse impact 
on the availability, affordability and accessibility of low-cost, high-quality medicines.” Grover envisaged a 
variety of scenarios including that medicines, deemed safe and effective by regulatory mechanisms, might 
be withheld at Kenyan checkpoints. He also predicted significant delays on imported generics and a drastic 
rise in the price of ARVs.
The adoption of similar regulations in other jurisdictions served a case in point to Grover’s argument. For 
example, both in the Netherlands and in Germany, after the passage of similar provisions as outlined in 
the Anti-Counterfeit Act, custom authorities had seized generic drugs for HIV, which were suspected to be 
counterfeits.
In 2012, three years after the Anti-Counterfeit Case was filed, the High Court of Kenya ruled that the 2008 
Anti-Counterfeit Act violated the rights to life, human dignity, and health as protected by the Constitution of 
Kenya. Justice Mumbi’s ruling affirmed that the provisions within the Act – particularly sections 2, 32, and 
34 which had construed “counterfeit” products with generics – had impinged upon Kenyan patients’ access 
to affordable and essential drugs and medicines, thereby infringing upon their fundamental rights to life, 
human dignity and health as protected by the Constitution of Kenya and in international instruments ratified 
in line with Article 2(6) of the Constitution.9 
Results and Lessons Learned 
The outcome of the Anti-Counterfeit Case reaffirmed the rights of Kenyan patients living with HIV/
AIDS and the obligation of the Kenyan government to fulfill its positive obligations towards them. In her 
8   Anti-Counterfeit Act, 2008 CAP. 130A (An Act of Parliament to prohibit trade in counterfeit goods, to establish the Anti-Counterfeit 
Agency, and for connected purposes).
9   Judgment: Petition No 409 of 2009, http://kelinkenya.org/wp-content/uploads/2010/10/Judgment-Petition-No-409-of-2009-Anti-counterfeit-
case.pdf.
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights © 2017 FXB Center for Health and Human Rights Health and Human Rights Resource Guide
Access to Medicines 
10.54
ruling, Judge Mumbi Ngugi stated, “There can be no room for ambiguity where the right to health and 
life of the petitioners and the many other Kenyans who are affected by HIV/AIDS are at stake.”10 The Anti-
Counterfeit case resulted in the suspension of significant portions of the Anti-Counterfeit Act, in particular 
relating to parallel importation. The court also issued a directive commanding the amendment of sections 2, 
32, and 34.11 Finally, the Court referenced paragraph 35 of General Comment No. 17 of the CESCR, stating that 
“[s]tates parties should prevent the use of scientific and technical progress 
for purposes contrary to human rights and dignity, including the rights to life, 
health and privacy, e.g. by excluding inventions from patentability whenever their 
commercialization would jeopardize the full realization of these rights.”12
Overall, the Anti-Counterfeit Case emphasized the importance of the right of the petitioners to access 
essential medicine over the protection of enforcing intellectual property rights. Moreover, it reaffirmed that 
the protection of consumers should not be a “collateral issue” in advancing the protection of intellectual 
property. The case has been deemed a milestone in the advancement of health and human rights in Kenya, 
and according to Allan Maleche, Executive Director of KELIN, it has since facilitated access to generic 
medicines for more than 430,000 people living with HIV in Kenya.
In addition to a strong litigation strategy on the part of KELIN and ALP, there were several other factors that 
contributed to the success of the litigation. For example, this case was particularly compelling because it 
coincided with the adoption of the Kenyan Constitution in 2010, which for the first time included the right 
to health. The recent codification of international human rights standards in Kenya’s national constitution 
also provided a robust discourse through which to advance justice in health. These constitutional changes 
importantly allowed the application of rights to health, dignity, and nondiscrimination, as enshrined within 
international human rights law, to drive arguments before the court. Once the petition was amended to 
reflect these constitutional changes in 2010, other key stakeholders, including the Special Rapporteur on the 
Right to Health, enjoined as interested parties.
In reflecting on the merits of the case, Maleche underscored the courage of the three Kenyans — Asero, 
Murenga, and Munyi — who bravely brought their testimonies before the court. Initially, the lawyers in the 
case had been poised to include several more testimonies in its application, but because of the entrenched 
stigma associated with HIV/AIDS in Kenya, several applicants withdrew their names. As such, the participation 
and bravery of Asero, Murenga, and Munyi in sharing their stories publicly was important and indispensable 
in advancing the case. 
Additional Resources
There are several resources to aide health right activists to understand the advances in right to health 
litigation and to help develop litigation strategies: B. M. Meier and A. E. Yamin, Right to Health Litigation 
and HIV/AIDS Policy, Journal of Law, Medicine & Ethics 39 (Spring 2011); S. Gloppen, “Litigation as a Strategy 
to Hold Governments Accountable for Implementing the Right to Health,” Health and Human Rights 10/2 
(2008), www.hhrjournal.org/index.php/hhr/article/viewFile/79/145.
Contact Information:
KELIN Nairobi, Kenya                                       Email:  info@kelinkenya.org                    Facebook: KELIN
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The Initiative for Medicines, Access & Knowledge (I-MAK) is a non-profit organization of lawyers and 
scientists representing the rights of low-income patients worldwide.  The organization believes all people 
have the right to access affordable, life-saving medicines for HIV/AIDS and other diseases. I-MAK expands 
access to lower-cost generic medicines by addressing legal and policy barriers, focusing on challenging 
unmerited drug patents, conducting evidence-based research on drug pricing and patents, and conducting 
advocacy and law reform efforts to drive practice-based solutions to access problems.
Problem 
In 2006, Lopinavir/ritonavir was considered the best drug combination available for patients who have failed 
HIV first line therapy.13 Because the tablet form does not need to be refrigerated nor does it require adherence 
to a strict dietary regimen, it is particularly well suited to patients in resource-constrained settings.14 However, 
access to Lopinavir/ritonavir was inhibited by Abbott Laboratories, the branded company that manufactured 
and sold the drug at the time. Abbott Laboratories, a major US pharmaceutical company, filed repeated 
requests to secure patents on various formulations of Lopinavir/ritonavir, a tactic that allowed Abbott to 
prolong exclusive rights over the combination and control the global market, setting the price out of reach 
for patients worldwide. A study of Abbott Laboratories patenting behaviour in the U.S. around Lopinavir/
ritonavir showed that it had accumulated a total of 108 different granted patents and patent applications.15 
Patient advocates, including I-MAK, deem pharmaceutical companies’ push to proliferate unjustified 
patents on essential drugs one of the biggest threats to people living with HIV. In this particular case, 
Abbot Laboratories filed a patent application with the Indian Patent Office and claimed its solid oral dosage 
formulation of Lopinavir/ritonavir—which had only been minimally modified—was “an invention.” 
If Abbott had secured a patent over this Lopinavir/ritonavir formulation, the repercussions would have 
been grave: Namely, other companies in India would have been prohibited from manufacturing affordable 
generics, which in turn would have limited access to treatment for millions of patients who could not afford 
Abbott’s hefty price tag. At the time, Lopinavir/ritonavir cost $2200 per patient, per year as its middle-tier 
price, and $500 per patient, per year at its lowest price.
Since India was one of the leading suppliers of affordable generics to other low- and middle-income countries, 
a patented Lopinavir/ritonavir would have dramatically hampered access to treatment for many individuals in 
developing countries around the world beyond India.16 
Actions Taken
On March 24th, 2006, Abbott Laboratories filed an application with the Indian Patent Office, claiming that 
13  I-MAK, “India Rejects Sham Patent Application for Lifesaving HIV Drug: Pharmaceuticals in India now free to help HIV patients worldwide,” 
press release, January 2, 2011, http://static1.1.sqspcdn.com/static/f/129694/10047500/1294018171907/FINAL+Press+Release+1-1-2011.
pdf?token=tGpdNo180J3KnXbdB33jTdjtoxg%3D
14 The treatment combination is recommended by the World Health Organization, the Clinton Foundation HIV/AIDS Initiative, Medecins Sans 
Frontieres, and The Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID.
15 Tahir Amin and Aaron S. Kesselheim, “Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs 
Could Be Extended for Decades,” Health Affairs 31/10 (2012), 2286-2294.
16 I-MAK, “Patents and HIV Medications: An Overview,” fact sheet, http://static1.1.sqspcdn.com/static/f/129694/10047507/1294018196787/
IMAK_FINALOverview+1-1-2011.pdf?token=yHodBvRmzldPdqWa%2BklwSrkRhmA%3D
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its solid oral dosage formulation of Lopinavir/ritonavir amounted to an invention that would not be known 
or obvious to anyone skilled in the field. To satisfy the requirements of the Indian Patent Act, Abbott also 
claimed that the alleged new formulation possessed a significant enhancement of efficacy of the formulation 
already known.
In 2007, I-MAK filed a patent opposition against Abbott’s tablet patent application following three other 
patent oppositions I-MAK filed against Abbott on related patents that could also potentially block generic 
companies. I-MAK claimed that Abbott’s formulation in question was “not an invention that should be 
considered patentable within the meaning of the Act” and submitted a body of scientific/legal evidence to 
support its contention. I-MAK’s patent challenge also contended, 
“[S]hould a patent be granted for the application in question, it will unfairly impede 
others from looking to develop and/or offer Lopinavir/ritonavir at more affordable 
prices. Moreover, it will contribute to preventing HIV patients from accessing this 
particular treatment at a cost they can afford.”17
I-MAK argued that in light of existing scientific knowledge and practices in the field, this tablet formulation 
lacked novelty and would have been obvious. I-MAK also argued that the formulation was a new form of a 
known substance that did not increase its efficacy over known forms. Therefore, it did not amount to an 
invention and was not patentable under the Act. 
The Indian Patent Office Decision denied Abbott’s a patent on the grounds that the new formulation was 
not inventive. Importantly, I-MAK’s intervention in India allowed Indian companies to produce and distribute 
much cheaper generic versions of Lopinavir/ritonavir.
Abbott’s attempt to patent lopinavir/ritonavir was also contested in other parts of the world, either filed 
or supported by I-MAK. I-MAK was able to file multiple patent challenges with the European Patent Office 
(covering 38 countries) on Abbott’s patent applications around lopinavir/ritonavir. In the United States, the 
Public Patent Foundation filed patent challenges against ritonavir. In Brazil, NGO Rebrip’s Working Group 
on Intellectual Property filed a pre-grant patent challenge to Abbott’s application on the heat-stable versions 
of LPV/r and ritonavir. 
According to Michelle Childs, former Director of Policy Advocacy of MSF Access Campaign, “Access to the 
drug lopinavir/ritonavir is critical for people living with HIV who have become resistant to their first medicine 
combination. Today we are concerned that access to this drug has shrunk with lopinavir/ritonavir now priced 
out of reach, which is quite worrying given the increasing number of people that need to switch to this drug.”18
Results and Lessons Learned
I-MAK’s challenge of Abbott’s patent applications was part of a larger scheme to reduce critical barriers to 
scaling up access to HIV treatment worldwide. “Abbott’s track record on pricing this drug unfairly for poorer 
countries motivated us to take on this case,” stated Tahir Amin, Director of I-MAK. “They have gamed the 
patent system for nearly twenty years to extend the patent life on this drug. The time has come to say, 
‘enough is enough’.
Facilitating the introduction of generics into the market is an important strategy in increasing access to 
medicines. According to I-MAK, cost-savings incurred over a three year period on just three HIV drugs - 
lopinavir/ritonavir, nevirapine and abacavir – generated a half billion dollars in cost savings, which can be 
17 I-MAK, Pre-Grant Opposition, http://static1.1.sqspcdn.com/static/f/129694/996699/1294009496187/I-
MAK+Pregrant+Opp+339+MUM+2006+.pdf?token=vjw3RSJ6CqDgkEQ54f68BlipssQ%3D. 
18 Médecins Sans Frontières, “Brazilians Demand Greater Access to Crucial HIV Drug,” November 10, 2011, https://msfaccess.org/resources/
press-releases/1682.
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re-invested in national health programs to put more people on treatment. Patent-legal interventions played 
a critical role in making lower-cost generic versions available globally.
“This groundbreaking victory for patients sets an important precedent to stop 
pharmaceutical companies from gaming the patent system, marking a new era of 
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The Center for Health, Human Rights and Development (CEHURD) is a health and human rights organization 
whose primary goal is enforce the realization of the right of health in Uganda. The organization empowers 
the community by making them aware of their rights inherent within the right to health. Working with 
government agencies and the Ministry of Health, CEHURD influences law and policy on the right to health, 
and through strategic litigation, provides pro bono legal services for those whose rights have been violated 
within the health system or neglected by the government.
The Problem 
In Uganda, the prevalence of malaria, tuberculosis, and HIV/AIDS is high. However, Ugandans face steep 
barriers in their pursuit of medicines that treat these very diseases.20 Many essential medicines are not 
available in government health facilities, and in the private sector, medicines are about 3-5 more expensive 
and unaffordable for most.21 Though the price of ARV medications to treat HIV/AIDS has decreased in recent 
years, most Ugandans still cannot afford them. 
CEHURD believes that the international trade regime has limited Uganda from realizing its obligation to 
respect the right to access medicines for its citizens. As this chapter has shown, strong IPR protection can 
drive up the prices of essential drugs and limit access to new medicines. Furthermore, certain provisions for 
patents under the TRIPS Agreement have prevented governments from addressing the public health needs 
of its citizens. 
As a least developed country (LDC), Uganda has no obligation to implement patents for medicines. However, 
CEHURD is concerned that the government will not maximize full flexibilities under the TRIPS Agreement – 
thereby maximizing the right to health – within its draft national legislation. According to CEHURD, crucial 
gaps within the Industrial Properties Bill “are likely to prejudice Uganda’s interventions in making medicines 
affordable and accessible for most Ugandans after the 2016 patents enforcement deadline.”
Actions Taken 
In anticipation of the 2016 patents enforcement deadline, CEHURD advocated for and worked with the 
government towards the inclusion of TRIPS flexibilities in the Industrial Property Bill of 2013. 
To garner governmental support, CEHURD developed a policy brief addressing the Industrial Property Bill, 
which made the case for striking a balance between the public interests of access to medicines and the 
private interest of intellectual property protection. In the brief, CEHURD urged the Ugandan government, 
in reforming its intellectual property laws, to maximize public health benefits from the new IPR protection 
regime by “making the most” of all flexibilities within TRIPS and adopting only the minimum levels of IPR 
protection that the Agreement requires.
Furthermore, CEHURD warned that the bill’s current formulation contained unnecessary IPR protection 
“over and above” the minimum required by the TRIPS Agreement. Current legislation also failed to fully 
utilize flexibilities that address national public health crises or make use of the transition period to incorporate 
TRIPS, which least developed countries (LDCs) can take advantage of. CEHURD also encouraged bolstering 
20 Ben Kiromba Twinomugisha, “Implications of the TRIPS Agreement for the Protection of the Right of Access to Medicines in Uganda,” 
Malawi Law Journal (2008), 253-278. 
21 Ibid.
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the capacity at the national level for the production of generic medicines and allowing “the widest possible 
scope” for parallel importation. Finally, CEHURD encouraged the government to “adopt a simple and 
expeditious procedure for compulsory licensing and government use order; allow extensive flexibility for 
scientific research and regulatory approval exceptions (bolar/early working provisions); and disallow data 
exclusivity, i.e. allow the submitted data to be relied upon by authorities in assessing and granting approvals 
for supply of medicines.”
As part of its initiative to influence the Industrial Properties Bill, CEHURD hosted a convening with CSOs and 
Anand Grover, the then Special Rapporteur on the Right to Health, on issues affecting access to medicines 
in Uganda. CEHURD also developed a booklet outlining its recommendations and compiled a mailing list of 
key stakeholders to facilitate national discussion on the matter.
Complementing their work on the Industrial Properties Bill, CEHURD developed comprehensive written 
materials for journalists in an effort to help shape communications on how information about access to 
medicines is delivered to the public. Written in clear language with policymakers and program planners in 
mind, the pocketbook Intellectual Property and Human Rights, outlines the basic concepts of intellectual 
property and several related public interest issues, including access to medicines. The publication also 
highlights significant gaps in the legislation in promoting Uganda’s public health needs and identifies 
interventions that have been proven to work for achieving better access to medicines, thus providing the 
evidence base for those designing policies and programs. The handbook helps maximize the efficiency and 
effectiveness of HIV programs by providing, in one place, evidence of successful and promising approaches 
and interventions. Intellectual Property and Human Rights is freely available online and in print for those 
with unreliable internet service, thus putting the evidence into the hands of those who cannot access or 
afford costly database subscriptions.
Lessons Learned 
CEHURD’s policy brief on the Industrial Property Bill was the basis for advocating and working with the 
government towards the inclusions of TRIPS flexibilities in the Industrial Property Bill. CEHURD demonstrated 
that not only was it necessary to provide for pro-access to medicines provisions in form of flexibilities, but 
that pro-access provisions are permitted within the scope of the international obligations which Uganda has.
The Intellectual Property and Human Rights was used together with fellowships and calls for media stories 
through which media were trained and requested to document access to medicines stories in the context of the 
need for a pro-access to medicines Industrial Property Bill. The successful dissemination of the pocketbook 
suggests that, in advocating for increased access to essential medicines, the media is an important resource 
for generating public discussion and raising awareness about access to medicines issues. If well informed on 
the issue, the media can be used as a tool to raise awareness, generate public discourse, and convey accurate 
messaging that advance the public’s cause. As a resource, Intellectual Property and Human Rights can guide 
effective, evidence-based programming, and highlight what remains to be done to advance access to medicines. 
Awareness of the full flexibilities under the TRIPS Agreement available to LDCs is only the first step. Identifying 
and implementing legislation that fully incorporates these allowances is the next step. Furthermore, when 
designing programs, policymakers and program planners have scarce resources and encounter a wide array 
of recommendations, best practices, scientific studies, and public health interventions.  Policymakers and 
programmers have been forced, at best, to undertake their own research to identify effective programming 
and, at worst, to base policies and programs on unquestioned practices. Until now, In Uganda, there has 
not been one central location to obtain a clear universal understanding of methods to advance the highest 
attainable standard of health.
Contact Information: CEHURD    Email:  info@cehurd.org     Web:  http://www.cehurd.org/
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The European Court of Human Rights
Open Society Georgia Foundation
Problem
Georgia has one of the highest rates of Hepatitis C incidence in the world (7%), only after Egypt and Mongolia.22 
The prevalence of the virus is especially high among populations infected with human immunodeficiency 
virus (HIV) (47%)23 and injection drug users (50%–70%).24 Before the change of government in 2012, HIV 
prevalence was also high among prisoners (50%).25  Though prison conditions have since improved, a 
constellation of factors—including overcrowding, poor nutrition and sanitation, inadequate health care, and 
insufficient infection control measures—had previously made ground especially fertile for the spread of 
Hepatitis C.
Before the government’s intervention described in this case study, the steep price of the Hepatitis C drug, 
Pegylated-Interferon, had also made treatment a distant dream for many.26 Out of 7% of the population 
infected with Hepatitis C, only 1% could afford the $18,000, 48-week course of treatment. Of prisoners, 
who depend on correctional facilities for their treatment, far fewer.27  Though treatment of prisoners with 
Hepatitis C puts a financial strain on prison systems, this did not absolve the government from providing 
treatment. Even so, the excessive price tag of Pegylated-Interferon, patent-protected by the duopoly of Roche 
and Merck, proved a significant barrier for the Georgian government.28
Actions Taken
Poghosyan v. Georgia, which was brought before the European Court of Human Rights (ECtHR) in 2009, 
was the watershed event that pressured the Georgian government to make medicines available to Hepatitis 
C patients in prisons. The applicant, Khvicha Poghosyan from Bodbiskhevi, Georgia, argued that his right 
to protection from inhumane and degrading treatment had been violated under Article 3 of the European 
Convention on Human Rights. After receiving post-operative care in the prison hospital for a cystectomy, the 
plaintiff was transferred to Prison No. 6 in Rustavi, Georgia, where blood tests revealed that Poghosyan had 
contracted Hepatitis C. Upon learning of his condition, the prison staff failed to transfer Poghosyan to the 
prison hospital to access the necessary care. In response, Poghosyan’s attorney filed a complaint with the 
Governor of the prison. This request was repeatedly denied. 
22 Reuters, “Gilead Uses Georgia as Free-Drug Testbed for Hepatitis C Elimination,” April 22, 2015, http://www.reuters.com/
article/2015/04/22/us-health-hepatitis-gilead-georgia-idUSKBN0ND1XU20150422
23 N. Chkhartishvili, L. Sharvadze, and O. Chokoshvili et al., “Mortality and Causes of Death among HIV-infected Individuals in the Country of 
Georgia,” AIDS Research and Human Retroviruses 30/6 (June 1, 2014), 1989–2012. 
24 E. Shapatava, K. E. Nelson, T. Tsertsvadze, and C. del Rio, “Risk Behaviors and HIV, Hepatitis B, and Hepatitis C Seroprevalence among 
Injection Drug Users in Georgia,” Drug and Alcohol Dependence 82/1 (2006), S35–8.
25 (Georgia’s Ministry of Labor, Health, and Social Affairs [MoLHSA], unpublished data, 2015), Center for Disease Control (CDC), “Launch of a 
Nationwide Hepatitis C Elimination Program — Georgia, April 2015,” http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6428a2.htm.
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It is important to note the Poghosyan v. Georgia case was not unique. In fact, Poghosyan v. Georgia was one 
of several cases linked to the denial of medical care in Georgian prisons brought before the ECtHR. At the 
time, approximately half of these applications related to inadequate treatment of Hepatitis C for patients in 
prisons.  As the ECtHR observed, these numbers suggested that “the problem of medical care in prisons, 
particularly care administered to detainees suffering from viral hepatitis C, inter alia, was a structural one.”29
The ECtHR ruled that the absence of Hepatitis C treatment in the prison constituted a violation of Article 3 
(prohibition of inhuman or degrading treatment) for the applicant, who was infected with Hepatitis C. In the 
context of Article 46 (binding force and execution of judgments), the Court said that the state had to comply 
with the Court’s judgment and take necessary individual and general measures to remedy the violation.30
The ruling subsequently obliged Georgia to create a program targeting the prevention and treatment of HCV 
in prisons. The Court’s decision also motivated the Georgian government to negotiate the price of Hepatitis 
C treatment with its producer, Roche and Merk. Backed by civil society and patient groups, negotiations 
brought down the price of Hepatitis C treatment by 60% for civilians.
Important Outcomes and Lessons Learned
The outcome of Poghosyan v. Georgia, and subsequent actions, demonstrates the ways in which a series 
of cases brought before the ECtHR can help facilitate legislative change to create programs for Hepatitis C 
patients in prisons and effectively reduce price barriers of medicines for populations in low-income countries. 
Legislation can play a key role in raising the profile of the problem and securing political commitment, paired 
with a combination of other tactics, including advocacy campaigns.
In this case, Open Society Georgia Foundation, along with lawyers and civil society organizations, partnered 
to assume an active role in developing jurisprudence on increasing the efficacy of treatment for incarcerated 
individuals with Hepatitis C. In developing an effective strategy, these parties focused their efforts on 
attacking one of the biggest barriers toward treatment – the exorbitant price tag of HCV treatment. In the 
aftermath of Poghosyan v. Georgia, Georgia’s prevention and treatment program has been lauded the first 
example of its kind amongst low- and middle- income countries and a model that other countries should 
follow.
Governments might also consider the prevalence of Hepatitis C in prisons as an important public health 
opportunity.31 If governments can effectively address the spread of Hepatitis C in prisons, the burden of 
disease in the population as a whole will drastically decrease. In fact, recent pharmaco-economic analyses 
suggest that treatment of Hepatitis C in prisons in the short term is a cost effective investment in the 
long term, reducing total HCV health expenditures.32 “There’s a tsunami of death and disease that’s already 
starting to crash down on us, and will continue to in the decades ahead,” Josiah Rich observed, who has 
written a new analysis on the matter. “But now that treatment can dramatically reduce transmission of this 
virus, we’re getting closer and closer to ending this epidemic. We argue that we should use the correctional 
system to do that.”33
29 European Court of Human Rights, “Structural inadequacy of medical care in prisons, in particular as regards the treatment of Hepatitis C: 
indication of appropriate legislative and other measures (Poghosyan v. Georgia)” in Information Note on the Court’s Case-Law, No. 116 
(February 2009), http://www.echr.coe.int/Documents/CLIN_2009_02_116_ENG_851318.pdf. 
30 Ibid. 
31 Josiah D. Rich, Scott A. Allen, and Brie A. Williams, “Responding to Hepatitis C through the Criminal Justice System,” New England Journal of 
Medicine 370, 1871-1874, http://www.nejm.org/doi/full/10.1056/NEJMp1311941. 
32 See Mina Marmor and Henry I. Miller, “A Public Health And Healthcare Spending Time Bomb: Hepatitis C” (June 19, 2013), http://www.
forbes.com/sites/henrymiller/2013/06/19/a-public-health-and-healthcare-spending-time-bomb-hepatitis-c/ on an assessment performed by 
the UK’s National Institute for Health and Clinical Excellence.
33 Josiah D. Rich, Scott A. Allen, and Brie A. Williams, “Responding to Hepatitis C through the Criminal Justice System,” New England Journal of 
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5. Where can I find additional resources on 
access to medicines and human rights?





• Patents and Human Rights 
• The Concept of Essential Medicines
• Access to Medicines and the Role of the Courts 
• Right to Life 
• Right to Health
• Right to Enjoy the Benefits of Scientific Progress and its Applications 
• Children
• Women
• Key Populations – Prisoners
• Key Populations – Patients with HIV/AIDS
• Key Populations – Patients with Cancer
• Key Populations – Patients with TB
• Key Populations – Older people
• Key Populations – Neglected diseases
• Websites
Medicine 370, pp. 1871-1874, http://www.nejm.org/doi/full/10.1056/NEJMp1311941. 
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A. International Instruments
Human Rights Council, Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health, A/HRC/23/L.10/Rev.1, June 11, 2013, https://documents-dds-
ny.un.org/doc/UNDOC/LTD/G13/147/13/PDF/G1314713.pdf?OpenElement. 
Human Rights Council, Elaboration of an International Legally Binding Instrument on Transnational 
Corporations and other Business Enterprises with Respect to Human Rights, A/HRC/26/L.22, 
June 26, 2014, https://documents-dds-ny.un.org/doc/UNDOC/LTD/G14/058/99/PDF/G1405899.
pdf?OpenElement. 
Office of the High Commissioner for Human Rights, Human Rights Guidelines for Pharmaceutical 
Companies in Relation to Access to Medicines in General Assembly of the UN Special Rapporteur on the Right 
to the Highest Attainable Standard of Health, A/63/263 (Aug. 11, 2008), http://www.ifhhro.org/images/
stories/ifhhro/documents_UN_special_rapporteur/3_4_8.pdf. 
UN Commission on Human Rights, Access to Medication in the Context of Pandemics such as HIV/AIDS, 
Tuberculosis and Malaria, Resolutions 2005/23, 2004/26, 2003/29 & 2002/32,  www.ohchr.org/EN/Issues/
HIV/Pages/Documents.aspx. 
UN Commission on the Status of Women, Women, the Girl Child and HIV and AIDS, Resolution 55/2, E/
CN.6/2011/L.3 (2011). www.un.org/womenwatch/daw/csw/csw55/other-outcomes/HIVandAIDS-adv-
unedit.pdf. 
The Limburg Principles on the Implementation of the International Covenant on Economic, Social 
and Cultural Rights, U.N. Doc. E/CN.4/1987/17, Annex at para. 17 and 18, https://www.escr-net.org/
docs/i/425445.
UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, U.N. Doc. 
E/C.12/2000/4 (Aug. 11, 2000). 
UN General Assembly, Report of the Special Rapporteur on the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health, Anand Grover, on access to medicines, A/HRC/23/42 
(May 1, 2013).
UN Doc. A/HRC 17/43: Report of the expert consultation on access to medicines as a fundamental 
component of the right to health.
UN Committee on Economic, Social and Cultural Rights, Human Rights and Intellectual Property, 27th 
Sess., ¶ 12, U.N Doc. E/C.12/2001/15 (2001).
UN Sub-Commission on Human Rights, Resolution 2000/7, Intellectual Property Rights and Human Rights, 
U.N. Doc. A/CN.4/L.682
World Health Organization, Constitution of the World Health Organization (adopted in 1946), http://www.
who.int/governance/eb/who_constitution_en.pdf. 
World Health Organization, Declaration of Alma-Ata (September 6-12, 1978), www.who.int/publications/
almaata_declaration_en.pdf.  
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Medicines in Africa, ACHPR/Res.141 (XXXXIIIII) 08 (November 2008).  www.achpr.org/sessions/44th/
resolutions/141/. 
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Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (1997). 
http://conventions.coe.int/Treaty/EN/Treaties/Html/164.htm. 
European Union, Programme for Action to Confront HIV/AIDS, Malaria and Tuberculosis (2007-2011), 
COM(2005) 179. http://europa.eu/legislation_summaries/development/sectoral_development_policies/
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World Health Organization, Scaling up response the response to HIV/AIDS in the European Region of WHO, 
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Charles T. Collins-Chase, “The Case against TRIPS-Plus Protection in Developing Countries Facing Aids 
Epidemics,” University of Pennsylvania Journal of International Law 29/763 (2014), http://scholarship.law.
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Médecins Sans Frontières, “The Impact of Patents on Access to Medicines,” http://www.msfaccess.org/
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Parliamentary Forum Training on Intellectual Property, Trade and Access to Medicines, May 14, 2009, Pretoria, 
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Organization resource, Implications of the Doha Declaration on the Trips Agreement and Public Health - Health 
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World Trade Organization, Understanding the WTO: The Agreements, “Intellectual property: protection 
and enforcement,” https://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm.
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E. The Concept of Essential Medicines
Hans V. Hogerzeil, “Essential Medicines and Human Rights: What Can They Learn From Each Other?” 
Bulletin of the World Health Organization 84 (2006), 371-375, http://www.who.int/bulletin/volumes/84/5/371.
pdf. 
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights © 2017 FXB Center for Health and Human Rights Health and Human Rights Resource Guide
Access to Medicines 
10.66
Ellen ‘t Hoen and Kaitlin Mara (with support from UNITAID), Ensuring that Essential Medicines are also 
Affordable Medicines: Challenges and Options (Geneva: World Health Organization, 2016), http://apps.who.
int/medicinedocs/documents/s22345en/s22345en.pdf. 
Word Health Organization, “The Selection of Essential Medicines,” Policy Perspectives on Medicines 4 
(2002).
World Health Organization, “Essential Medicines,” http://www.who.int/topics/essential_medicines/en/. 
F. Access to Medicines and the Role of the Courts
Alicia Ely Yamin and Siri Gloppen (eds), Litigating Health Rights: Can Courts Bring More Justice to 
Health? (Cambridge, MA: Harvard University Press, 2011).
Hans V. Hogerzeil, Melanie Samson, Jaume Vidal Casanovas, et al., “Is Access to Essential Medicines as 
Part of the Fulfilment of the Right to Health Enforceable Through the Courts?” Lancet 368 (2006), 305–11, 
http://www.who.int/medicines/news/Lancet_EssMedHumanRight.pdf.
Ole Frithjof Norheim and Bruce M. Wilson, “Health Rights Litigation and Access to Medicines: 
Priority Classification of Successful Cases from Costa Rica’s Constitutional Chamber of the Supreme 
Court,” Health and Human Rights 16/2 (October 2014), http://www.hhrjournal.org/2014/10/02/health-
rights-litigation-and-access-to-medicines-priority-classification-of-successful-cases-from-costa-ricas-
constitutional-chamber-of-the-supreme-court/. 
G. Access to Medicines and the Role of Pharmaceutical Companies
Emmanuel Oke, “Using the Right to Health to Enforce the Corporate Responsibilities of Pharmaceutical 
Companies with Regard to Access to Medicines,” Journal of Health Diplomacy 1/1 (July 2013), http://
papers.ssrn.com/sol3/papers.cfm?abstract_id=2332604. 
Lisa Forman and Jillian Clare Kohler (eds), Access to Medicines as a Human Right: Implications for 
Pharmaceutical Industry Responsibility (Toronto: University of Toronto Press, 2012). 
Sofia Gruskin and Zyde Raad, “Are Drug Companies Living Up to Their Human Rights Responsibilities? 
Moving Toward Assessment,” PLoS Medicine 7/9 (September 2010), http://journals.plos.org/
plosmedicine/article?id=10.1371/journal.pmed.1000310. 
H. Right to Life
P. De Vos et al, “Health Through People’s Empowerment: A Rights-based Approach to Participation,” 
Health and Human Rights 11/1 (2009),  www.hhrjournal.org/index.php/hhr/article/view/126/201. 
Alicia Ely Yamin, “Suffering and Powerlessness: The Significance of Promoting Participation in Rights-
Based Approaches to Health,” Health and Human Rights 11/1 (2009), 5-22, www.hhrjournal.org/index.php/
hhr/article/view/127/200. 
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights
Access to Medicines 
10.67
I. Right to Health
BMA and the Commonwealth Medical Trust, The Right to Health: A Toolkit for Health Professionals (June 
2007), http://www.ifhhro.org/our-work/our-publications/353-the-right-to-health-a-toolkit-for-health-
professionals-2007.
Hans V. Hogerzeil and Zafar Mirza, “Access to Medicines as Part of the Right to Health,” in The World 
Medicines Situation 2011 (Geneva: WHO, 2011), http://apps.who.int/medicinedocs/documents/s18772en/
s18772en.pdf. 
Office of the High Commissioner for Human Rights and World Health Organization, The Right to Health, 
Fact Sheet No. 31, http://www.ohchr.org/Documents/Publications/Factsheet31.pdf.
Stephen P. Marks, “Access to Essential Medicines as a Component of the Right to Health” in Health: A 
Human Rights Perspective, https://cdn1.sph.harvard.edu/wp-content/uploads/sites/580/2012/10/marks_
access_to_essential_medecines-2009.pdf.
UN General Assembly, Report of the Special Rapporteur on the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health, Anand Grover, on access to medicines, A/
HRC/23/42 (May 1, 2013).
J. Right to Enjoy the Benefits of Scientific Progress and its Applications
UN Committee on Economic, Social and Cultural Rights, General Comment No. 17: The right of everyone 
to benefit from the protection of the moral and material interests resulting from any scientific, literary or artistic 
production of which he is the author (art. 15 (1) (c)), E/C.12/GC/17 (2006), http://tb.ohchr.org/default.
aspx?Symbol=E/C.12/GC/17.  
K. Children
World Health Organization, Essential Medicines for Children:  Background Information: Child-specific 
medicines: A global priority, http://www.who.int/childmedicines/media/backgrounder/BG1/en/. 
L. Women
Human Rights Watch, “Stop Making Excuses”: Accountability for Maternal Health Care in South Africa (HRW, 
August 2011), http://reliefweb.int/sites/reliefweb.int/files/resources/Full_Report_2004.pdf. 
World Health Organization, WHO Recommendations for the Prevention and Treatment of Postpartum 
Haemorrhage (Geneva: WHO, 2012).
M.  Key Populations – Prisoners
Rick Lines, “The Right To Health of Prisoners in International Human Rights Law,” International Journal of 
Prisoner Health 4/1 (March 2008), 3-53,  www.ahrn.net/library_upload/uploadfile/file3102.pdf
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights © 2017 FXB Center for Health and Human Rights Health and Human Rights Resource Guide
Access to Medicines 
10.68
N. Key Populations – Patients with HIV/AIDS
Brazilian International AIDS Association/ Global AIDS Policy Watch, “HIV and AIDS in the mandate of 
the Special Rapporteur on the Right to Health: genealogies, lessons learned, challenges that remain,” 
December 10, 2014, http://abiainternacional.fw2.com.br/news/articles/hiv-and-aids-genealogies-lessons-
learnd-and-challenges/124.
Human Rights Watch (HRW), “The FTAA, Access to HIV/AIDS Treatment, and Human Rights,” Briefing 
Paper, October 29, 2002, https://www.hrw.org/report/2002/10/29/ftaa-access-hiv/aids-treatment-and-
human-rights/human-rights-watch-briefing-paper. 
Lisa Forman, “A Transformative Power? The Role of the Human Right to Medicines in Accessing AIDS 
Medicines – International Human Rights Law, TRIPS, and the South African Experience” (SJD dissertation, 
University of Toronto, 2007).
World Health Organization, Bulletin of the World Health Organization, “Access to AIDS medicines 
stumbles on trade rules,” http://www.who.int/bulletin/volumes/84/5/news10506/en/.
O. Key Populations – Patients with Cancer
Ellen ‘t Hoen, Access to Cancer Treatment: A Study of Medicine Pricing issues with Recommendations 
for Improving Access to Cancer Medication (Oxford: Oxfam International, 2015), http://apps.who.int/
medicinedocs/documents/s21758en/s21758en.pdf.
P. Key Populations – Patients with TB
Ann M. Ginsberg and Melvin Spigelman, “Challenges in Tuberculosis Drug Research and Development,” 
Nature Medicine 13/3 (March 2007), http://www.tballiance.org/newscenter/research_papers/
NatMed13_290_GinsbergSpigelman_Challenges%20in%20tuberculosis%20drug%20research%20
and%20development.pdf.
Q. Key Populations – Older People
International Narcotics Control Board, Report of the International Narcotics Control Board on the Availability 
of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes (2010), 
http://www.unodc.org/documents/southerncone/noticias/2011/03-marco/Jife/Report_of_the_Board_on_
the_availability_of_controlled_substances.pdf. 
International Association for Hospice and Palliative Care, IAHPC List of Essential Medicines for Palliative 
Care (2007), http://hospicecare.com/resources/palliative-care-essentials/iahpc-essential-medicines-for-
palliative-care/.
Manfred Nowak and Anand Grover, Joint letter by UN special rapporteur on the prevention of torture and 
cruel, inhuman or degrading treatment or punishment, Manfred Nowak, and the UN special rapporteur on 
the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, Anand 
Grover, to the Commission on Narcotic Drugs (December 2008). http://www.hrw.org/news/2008/12/10/un-
human-rights-experts-call-upon-cnd-support-harm-reduction.
M.E.C. Gispen, “A Human Rights View on Access to Controlled Substances for Medical Purposes under 
the International Drug Control Framework,” European Journal of Pharmacology 16 (2013).
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights
Access to Medicines 
10.69
R. Neglected Diseases
UNICEF, UNDP, World Bank, World Health Organisation Special Programme for Research and Training in 
Tropical Diseases.
Mary Moran, Anne-Laure Ropars, Javier Guzman, et al., The New Landscape of Neglected Disease Drug 
Development (London: The Wellcome Trust, 2005), http://www.policycures.org/downloads/The_new_
landscape_of_neglected_disease_drug_development.pdf. 
S. Websites
European Public Health Alliance: http://www.epha.org. 
Health Rights: Human Rights in Patient Care:  www.health-rights.org/.  
Physicians for Human Rights: physiciansforhumanrights.org/. 
www.accesstomedicines.org. 
Health and Human Rights Resource Guide © 2017 FXB Center for Health and Human Rights © 2017 FXB Center for Health and Human Rights Health and Human Rights Resource Guide
Access to Medicines 
10.70
6. What are the key terms related to access to 
medicines and human rights?
A 
Antiretroviral (ARV) and Antiretroviral Treatment (ART)
A medicine for the treatment of HIV. There are several classes of ARVs, which all target a different phase in 
the reproductive cycle of the virus. ART is a treatment regimen composed of several ARVs (usually three).34
B
Bolar exemption
A legal exemption that permits the use of patented invention before the patent expires for the purposes of 
obtaining marketing approval of a generic for commercialization once the patent expired.35
C
Compulsory license/ government use
A compulsory licence is an authorisation by a competent government authority to use a patented invention 
by a third party without the consent of the patent holder, against a payment of “adequate remuneration.” A 
‘government use’ is a particular form of compulsory licence issued by the government for its own use or for 
the use of a third party.36 
Counterfeit medicine
WHO defines counterfeit medicine as “[a] medicine which is deliberately and fraudulently mislabelled 
with respect to identity and/or source. Counterfeiting can apply to both branded and generic products 
and counterfeit products may include products with the correct ingredients or with the wrong ingredients, 
without active ingredients, with insufficient active ingredients or with fake packaging.”37
D
Data exclusivity
Data exclusivity is the prohibition of use of pharmaceutical test data submitted to a regulatory agency by an 
originator company for the purpose of registering a generic drug. Generic companies rely on this test data to 
demonstrate the safety and efficacy of their bioequivalent drug. Delayed use of the data will therefore delay 
the registration and marketing of generic medicines, regardless of the patent status of the product.38
Delinkage
A term used to describe a key characteristic of any financing model of innovation characterized by the 
uncoupling of R&D costs and consume prices for health technologies. Examples of delinkage models 
34 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
146. 
35 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 5.
36 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
146. 
37 See WHO, Guidelines to Develop measures to combat counterfeit drugs, WHO/EDM/QSM 99.1 (1999),
      http://whqlibdoc.who.int/hq/1999/WHO_EDM_QSM_99.1.pdf. 
38 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
146. 
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include grants, prizes, and advance market commitments, among others.39
Doha Declaration on TRIPS and Public Health
The fourth World Trade Organization (WTO) ministerial conference in 2001 in Doha, Qatar responded to 
the public health concerns fuelled by the HIV/AIDS crisis by adopting the Doha Declaration on the Trade-
Related Aspects of Intellectual Property Rights Agreement (TRIPS) and Public Health. The Doha Declaration, 
as it is widely known, affirmed the sovereign right of governments to take measures to protect public health, 
including the use of compulsory licensing and parallel importation. It also allowed least developed countries 
(LDCs) not to grant or enforce pharmaceutical product patents until at least 2016.40
E
Essential medicines
Essential medicines are those that satisfy the priority health care needs of the population. They are selected 
with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness.
Essential medicines are intended to be available within the context of functioning health systems at all times 
in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and 
at a price the individual and the community can afford.41
Essential Medicines List (EML)
The EML is a list maintained by the World Health Organization that contains the most important medicines 
that should be available and affordable to the communities and people that need them. The EML is a tool 
for governments and healthcare providers seeking to meet the health needs of their populations. The EML 
is updated periodically to detail the medicines a health system should seek to make available.42
Evergreening
The practice of seeking secondary patents with the aim to extend market exclusivity beyond the patent term 
of the basic patent.43
H
Health 
Complete physical, mental, and social well-being, rather than merely the absence of disease or infirmity 
(World Health Organization). 
I
Intellectual property (IP)
Intellectual property (IP) refers to the legal rights that result from intellectual activity in the industrial, 
scientific, literary and artistic fields. IP has two branches: Industrial property (e.g., inventions (patents), 
trademarks, industrial designs, geographical indications) and copyright (and related rights).44
39 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 5.
40 Ellen ’t Hoen, “Turning the Tide: The WTO Doha Declaration on TRIPS & Public Health,” in Private Patents and Public Health: Changing 
Intellectual Property Rules for Access to Medicines (The Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-
content/uploads/private-patents-and-public-health.pdf, p. 31. 
41  WHO, “Health Topics: Essential Medicines,” http://www.who.int/topics/essential_medicines/en/, accessed on January 25, 2017.
42  Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The
       Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p.
       146. 
43  Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The  
       Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
      146. 
44 Ibid., p. 147. 
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Diseases for which there is a lack of sufficient medical innovations, resulting in inadequate, ineffective 
or non-existent means to prevent, diagnose, and treat them. The lack of sufficient medical innovation is 
often rooted in an absence of market incentives owing to the low purchasing power of the populations 
disproportionately affected by such conditions.45 
O
Orphan disease
A disease that affects only small numbers of individuals. The threshold number varies from country to 
country. An orphans disease may affect fewer than 2000,000 individuals (United States), fewer than 50,000 




Parallel importation refers to the import and resale in a country, without the consent of the patent holder, of 
a patented product that has been legitimately put on the market of the exporting country. Parallel imports 
take place when there are significant price differences for the same good in different markets.47
Patent
A patent is a form of IP granted to an inventor for the creation of something new, non-obvious to a person 
who is knowledgeable in the field, and useful. Patents grant a temporary monopoly (usually 20 years), during 
which time the patent holder can prevent others from making, using, or selling their invention. A patent is 
national in nature, and inventors must apply under each countries patent laws in order to receive protection 
in that country. In international trade, however, a blocking patent in either the country of import or export 
could interfere. That 148 ANNEXES means a patent in a country that produces lots of generic medicines, 
such as India, can be enough to restrict access to those medicines in other countries relying on the first 
country’s exports, regardless of whether or not there is a patent in the importing country.48
Patentability criteria
Requirements that must be satisfied before a patent is awarded. These are (1) subject matter for eligibility, 
(2) novelty, (3) an inventive step and (4) industrial application. The precise nature of these requirements 
is not defined in the TRIPS Agreement and it is up to countries to define these in their laws and policies.49
Patent pools
An agreement among patent holders to voluntarily license a set of their patents to one another or to third 
parties. Patent pools are often administered or managed by institutional frameworks to facilitate the 
negotiation of such agreements.50
45 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 5.
46 Ibid.
47 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
147. 
48   Ibid. 
49 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 6.
50 Ibid.
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Patient 
A user of health care services, whether healthy or sick (Declaration on the Promotion of Patients’ Rights in 
Europe, WHO, Amsterdam 1994).
A person in contact with the health system, seeking attention for a health condition (European Observatory 
on Health Systems and Policies). 
S
Stigma and discrimination 
The United Nations has called stigma and discrimination associated with HIV and AIDS “the greatest 
barriers to preventing further infections, providing adequate care, support and treatment and alleviating 
impact.” Stigmatization leads to discrimination.
• Stigma is “a powerful discrediting and tainting social label that radically changes the way individuals 
view themselves and are viewed as persons.” People who are stigmatized are usually considered 
deviant or shameful for some reason or other, and as a result are shunned, avoided, discredited, 
rejected, restrained or penalized. As such, stigma is an expression of social and cultural norms, 
shaping relationships among people according to those norms. Stigma marks the boundaries a 
society creates between “normals” and “outsiders,” between “us” and “them.”
• Discrimination “refers to unfair or unjustifiably adverse treatment.”51  Discrimination can be 
legitimate and illegitimate. Illegitimate discrimination is unjustified, disproportionate, and arbitrary. 
A measure or an action is unjustified if it lacks rational and objective reasons. It is disproportionate 
if the means employed and their consequences far exceed or do not achieve the aims pursued. It is 
arbitrary if it seriously infringes the rights of the individual and is not necessary to protect the health 
of others.  
T
The Trade Related Aspects of Intellectual Property Rights Agreement (TRIPS)
Administered by the World Trade Organization, TRIPS sets out minimum standards for the protection of 
several forms of IP that all World Trade Organization member countries need to implement. TRIPS also 
contains several important flexibilities to preserve the rights of nations to protect the public interest.52
TRIPS flexibilities 
A term used broadly to describe a set of norms, rules, and standards that allow variations in the implementation 
of the TRIPS Agreement obligations, including limits on the exercise of intellectual property rights.53
TRIPS-Plus/ TRIPS+
These are measures that require more stringent IP standards than those contained in TRIPS or that limit 
flexibilities inherent in TRIPS. They are often contained in bilateral or regional trade agreements, and are a 
matter of concern for public health advocates.54
51 Frederick M. Abbot, “Compulsory Licensing for Public Health Needs: The TRIPS Agenda at the WTO after the Doha Declaration on Public 
Health” (Quaker United Nationals Office, Geneva: February 2002), 49, www.quno.org. 
52 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
148. 
53 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 6.
54  Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
148. 
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A license granted by a patent holder to a third party to produce and/or market and distribute a patented 
product, usually in exchange for a royalty on net sales and certain other conditions (for example, geographical 
restrictions on where the product can be sold).55
W
World Health Assembly (WHA)
Attended by health ministers from World Health Organization member states, the WHA is the most 
important World Health Organization (WHA) governing body, setting the direction and priorities for the 
organisation at its annual meeting. 56
WHO
The Word Health Organization (WHO) is the directing and coordinating authority on international health 
within the United Nations’ system. The WHO does this by: providing leadership on matters critical to health 
and engaging in partnerships where joint action is needed; shaping the research agenda and stimulating 
the generation, translation and dissemination of valuable knowledge; setting norms and standards and 
promoting and monitoring their implementation; articulating ethical and evidence-based policy options; 
providing technical support, catalysing change, and building sustainable institutional capacity; and 
monitoring the health situation and assessing health trends.57
WIPO
The World Intellectual Property Organization (WIPO) is the global forum for intellectual property services, 
policy, information and cooperation. It is a self-funding agency of the United Nations, with 189 member 
states.58
WTO
The World Trade Organization (WTO) is the only global international organization dealing with the rules 
of trade between nations. At its heart are the WTO agreements, negotiated and signed by the bulk of the 
world’s trading nations and ratified in their parliaments. The goal is to ensure that trade flows as smoothly, 
predictably and freely as possible.59
55 “Glossary” in High-Level Panel on Access to Health Technologies, Report of the United Nations Secretary-General’s High-Level Panel on Access 
to Medicines: Promoting Innovations and Access to Health Technologies (Geneva: UNHLP, September 2016), https://static1.squarespace.com/
static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf, p. 6.
56 Ellen ’t Hoen, “Annex 4: Glossary,” in Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines (The 
Netherlands: Health Action International, 2016), http://accesstomedicines.org/wp-content/uploads/private-patents-and-public-health.pdf, p. 
148. 
57 World Health Organization, “About WHO” fact sheet, http://www.who.int/about/what-we-do/en/. 
58 World Intellectual Property Organization, “Inside WIPO” fact sheet, http://www.wipo.int/about-wipo/en/. 
59 World Trade Organization, “The WTO” fact sheet, https://www.wto.org/english/thewto_e/thewto_e.htm. 
